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ABSTRACT OF THE DISSERTATION
Understanding the Influence of Individual-level Sources of Pathology Variation on
Neuroimaging Measures of Alzheimer Disease
for Arts & Sciences Graduate Students
by
Austin A. McCullough
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2022
Professor Tammie L.S. Benzinger, Chair
Professor Carlos Cruchaga, Co-Chair
The overall goal of this dissertation is to gain a better understanding of how current
Alzheimer disease pathologic progression models interact with sources of individual-level
variation in pathology to influence overall disease progression in a clinically meaningful way.
Many sources of variation, both internal (e.g., genetic mutations, heterogeneity of tau pathology)
and external (e.g., diet and exercise, sleep quality), are known to influence disease progression
and symptom onset in AD. With the advent of therapies that have shown successful reduction of
amyloid load in trials and the rapid progression of anti-tau therapies, we hypothesize that a better
understanding of how these sources of pathology variation interact with and modify the
pathological cascade will allow future studies to appropriately take these factors into account and
assist in clinical decision making when it comes to therapeutic treatment of Alzheimer disease.
In chapter 2 we examine the concurrent influences of tau and Aβ pathology and separate the
influences of each pathology on grey matter structural integrity. We show that tau pathology is
xiii

highly correlated with antecedent longitudinal change in cortical thickness and is likely the
driving force behind both tau and Aβ correlations with cortical thickness loss in prior work. The
higher levels of heterogeneity in tau pathology between individuals compared to diffuse cortical
Aβ pathology suggests greater room for individual pathology trajectory differences to arise. In
chapter 3 we show that the important external factors of sleep quality and BMI levels have
profound influence on AD pathological development at an individual level and suggest that
further work is needed to integrate the effects of these disease modifying factors into disease
modeling strategies. In chapter 4 we highlight the difficulties in accounting for sources of
individual pathology variations in current longitudinal disease modeling strategies and propose a
new methodology for making individual-level disease progression predictions while accounting
for these sources of individual pathology variations. In chapter 5 we show that effectiveness of
an anti-amyloid therapy varies largely, but not solely, with how much Aβ pathology is present
within an individual or region and suggest that regional levels of different Aβ plaque
conformations may influence results.

xiv

Chapter 1: Introduction
1.1 Alzheimer Disease Continuum

When Alzheimer disease (AD) was first characterized as a distinct form of dementia by Alois
Alzheimer around a century ago, he used new developments in histological techniques to
visualize pathologies in the brain of one recently deceased individual: Auguste Deter. Many
subsequent studies followed and the number of individuals whose postmortem pathology was
characterized quickly grew with the desire to understand the pathology in this group of
individuals vs. the other group (individuals with other forms of dementia). Although the
methodologies and techniques used to study those suffering from AD has changed dramatically
since this time, group-level analysis has maintained a dominant presence in AD research and
publications. Postmortem histological studies in progressively larger groups of brains acquired at
autopsy allowed early researchers to stage both the diffuse cortical buildup of amyloid-β plaque
deposits1,2 and the latter, more targeted buildup of tau proteins in the form of neurofibrillary
tangles (NFTs)1–3. Out of these characterizations, researchers began to develop theories on how
these seemingly disparate pathologies ultimately resulted in the large-scale cortical thickness loss
and cognitive deficits present in the symptomatic phase of AD, and concepts such as the amyloid
cascade hypothesis were born4.
Despite having enough data to outline theories on the sequence of pathology
development, researchers needed increasing amounts of data in order to solidify their respective
theories and thus began looking for ways to dynamically monitor the buildup of proteinopathies
and the associated structural loss and neuronal dysfunction in the brains of living humans. In the
early 1990s, it was found that Aβ is generated as a soluble protein during normal cellular
1

metabolism and is secreted into the cerebrospinal fluid (CSF)5. This led to the emergence of CSF
metabolite assays to monitor levels of multiple specific forms of Aβ, total tau (T-tau), and
multiple phosphorylated forms of tau (P-tau)6,7; techniques that are widely used in the present
day7. Around the same time researchers began using structural magnetic resonance imaging
(MRI) for monitoring volumetric changes in the brains of participants8–11. Further progress in
advanced MRI techniques led to the use of functional MRI (fMRI) to measure synaptic integrity
and circuit connectivity (resting state fMRI)11,12 as well as diffusion MRI (DTI) to measure white
matter integrity11,13. Another type of imaging, positron emission tomography (PET), allowed
researchers to design radioligands that bind to and track the presence and evolution of specific
molecules in the brain11. 18F-2fluoro-2-deoxy-D-glucose (FDG) PET was designed to provide
insight into alterations in brain glucose metabolism11,14. Several different radioligands (e.g. 11C
PiB, 18F AV-45) were developed to bind to fibrillar amyloid-β and provide deposition maps of
the protein11,15. More recently, radioligands designed to bind to tau NFTs such as 18F AV-1451
and 18F MK-6240 have begun widespread use for monitoring tau pathology buildup11. Other
radioligands to monitor markers of neuroinflammation (TSPO PET), certain epigenetic changes
like histone protein deacetylation (HDAC PET), and synapse loss (11C-UCB-J PET)11 are still
being characterized and validated for widespread use.
The presence of these pathology monitoring modalities should be thought of as tools
in a tool belt that researchers continue to use to develop a better understanding of pathologic
processes in AD. By far, the most valuable consequence of these modalities’ availability is the
opportunities they provide for real-time, repeatable data collection at any time in the disease
course. This led to an incredible proliferation of available cross-sectional data in living subjects
and allowed many research centers to launch large-scale longitudinal studies following cohorts
2

of subjects through large chunks of the disease course. Researchers began to be able to better
piece together high dimensional models of pathology evolution throughout the disease course.
The most prominent of these models was the aforementioned amyloid cascade hypothesis4,
which was updated and expanded with new biomarkers as they became available 16,17. The
amyloid cascade hypothesis lays out a sequence of pathologic changes that occur in AD,
proposing that the proliferation of amyloidosis leads to the formation of tau NFTs, which in turn
leads to neuronal dysfunction and neurodegeneration ultimately causing cognitive impairment
(Figure 1.1)16,17. Additional datasets have been shown to support this serial change in biomarkers
in different populations (Figure 1.2)18,19.

3

Figure 1.1. AD biomarker cascade model. (Adapted from Jack et al., 2010 and Jack et al., 2013).

Figure 1.2. (Bateman et al., 2012). AD cascade in the dominantly inherited Alzheimer network (DIAN).

4

The presence of AD biomarkers has taken on increasing importance in diagnostic and
clinical settings as well. In 2011, the National Institute on Aging (NIA) included biomarker data
as part of the diagnostic criteria when codifying the preclinical stage of AD20, recommending
clinicians to incorporate biomarker analyses rather than rely purely on symptom presentation.
This served to begin the shift towards a more biological definition of AD, a move most clearly
defined in 2018 with the proposal of the A/T/N framework21. The A/T/N framework clearly used
amyloid and tau pathology buildup to define what should be considered part of AD. It also
helped to shift the discussion of AD pathology further towards a ‘continuum’ approach, where
gradual buildup of pathologies over time is observed and used to determine an individual’s
position within the disease course.

1.2 Origins of Pathology Heterogeneity in AD

Despite the well-documented utility of pathology progression models based on group-level
analysis to give an overall picture of disease progression in AD, many significant modifiers of
pathological trajectories have been characterized that make application of these models to
individual cases difficult. Genetic mutations represent by far the most impactful of these
modifiers.
As genetic analyses became increasingly common in disease research, a report in
1987 linked a rare form of familial inherited AD, where cognitive symptom onset happens at
much younger ages than typical AD, to a region on the long arm of chromosome 21 that
harbored the gene encoding the amyloid-β protein precursor (APP)22. By 1991, the first of more
than 30 known specific mutations of the APP gene23 was described in detail24. Only a year later,
the discovery of a second linkage region25–27 led to the eventual characterization of the presenilin
1 (PSEN1) gene28, which plays an essential role in mediating the processing of APP to generate
5

Aβ29. Presenilin 2 (PSEN2) was discovered and characterized shortly after30,31. Mutations in any
of these genes accelerate the cleavage of APP into amyloidogenic forms of amyloid-β (Aβ40 and
Aβ42) to such a degree that amyloid-β deposition begins the AD pathological cascade as early as
an individual’s 30s or 40s18,19. This much earlier pathology onset, coupled with some differences
in spatial presentation of Aβ plaque buildup and the strong familial inheritance, have led to these
mutations being defined as a subset of AD called dominantly inherited Alzheimer disease
(DIAD) or early onset familial Alzheimer disease (EOAD).
Genetic mutations have also been shown to have profound effects on risk of
developing AD and pathology trajectories in the much more common late onset (LOAD) or
senile form of AD. In the early 1990s, studies began demonstrating that people with
apolipoprotein ε4 (ApoE4) alleles were at increased risk for developing AD32, decreased the age
of onset in mutation carrying individuals in a dose-dependent manner, and showed greater
cognitive decline even in individuals who did not yet meet clinical diagnostic criteria for
dementia33–35. These results motivated researchers to look for other genetic factors that could
affect LOAD, and several chromosomal regions were found that showed evidence for genetic
linkage from full-genome linkage studies36. Advancements in genome sequencing technologies
have allowed researchers to identify continually increasing numbers of risk loci via genome-wide
association studies in AD37–40.
Epigenetic changes represent another key facilitator of pathology variation, with
large-scale changes in gene accessibility and transcription levels potentially modifying levels of
key proteins that could impact disease progression in a host of ways41,42. Many researchers have
published extensively in this area in the last decade, with DNA methylation levels41–46,

6

chromatin remodeling and histone modifications42,47–49, and miRNA levels50–52 all demonstrating
potential for pathology modification in AD53,54.
Overall, these genetic and epigenetic sources of pathology variation focus on
alterations in levels of key protein production, alterations in probabilities of protein deposition
(e.g. cleaving site probabilities, protein folding probabilities), or alterations in levels of protein
processing and clearance. These pathways of impacting pathology variation can also be affected
by many external factors outside of the direct biochemical pathways.

7

1.3 Everything is Connected: How Health and Life Factors
Can Influence Risk and Pathology Progression

In recent years, regular physical activity has emerged as a powerful protective factor against AD
pathology progression and cognitive decline. Mild-to-moderate physical exercise has ranked
highly in several risk factor meta-analysis studies55–57, and shown tangible benefits to cognition
in randomized controlled trials58–60. Exercise-induced alteration of vascular physiology and/or
neurogenesis pathways have been suggested as the mechanisms behind these benefits. Moderateintensity exercise has been shown to cause significant augmentation of blood flow to the
brain61,62, as well as strengthening of vascular and circulatory systems61,62. Physical exercise has
also been shown to protect against hippocampal volume loss63 and even increase hippocampal
volume59,60,63, providing a pathway for countering episodic-like memory deficits seen in AD64,65.
Nutritional patterns have also been correlated with AD incidence in several studies,
indicating that diet acts as a modifiable risk factor66–68. This is potentially due to the effects of
diet on the diversity and taxonomic differences in gut microbiota69–71, which can have diverse
and long reaching effects. Studies have associated gut microbiome modifications with increased
levels of proinflammatory cytokines such as interleukin 1 (IL-1) and IL-6 in the blood, which can
cross the blood brain barrier and act on neuronal receptor and microglia to alter their activation
state and physiology72–76. Dysbiosis in the gut microbiota has also been shown to influence
GABA production in the intestine and lead to a decrease in levels of GABA in the CNS77.
GABAergic neurotransmission has been shown to undergo pathological alterations in AD78,79.
Hyperglycemia, a main characteristic of obesity and type II diabetes, has been shown
to increase brain insulin resistance and affect amyloidogenesis by inducing neuroinflammation,
oxidative stress, and mitochondrial dysfunction80. Chronic hyperinsulinemia present in brain
insulin resistance limits available insulin by reducing insulin transporters in the blood brain
8

barrier, allowing less insulin to reach dedicated receptors present in the hippocampus and
therefore impairing memory consolidation81–86. Evidence from mouse models and human cell
cultures also suggests that hyperglycemia increases amyloid-β production by inhibiting APP
degradation in neuronal-like and non-neuronal cells80,87.
Sleep and AD pathology, which we will cover in detail in chapter 3, also have
significant interactions88–90. Sleep-wake activity is disturbed in individuals with AD91,92.
Continually increasing evidence also supports sleep disturbance as a marker for future risk of
cognitive impairment and as a marker for AD pathology93–100. Amyloid-β concentrations are
directly regulated by neuronal activity101–103 and evidence suggests that amyloid-β clearance is
increased during sleep due to increased interstitial fluid (ISF) bulk flow104.
The ongoing theme with all these health factors and their relationships with AD
pathology progression is that these factors synergistically contribute to how efficient an
individual’s neural circuitry is at maintaining optimal function, particularly with regards to
proper metabolite production, processing, and clearance. A rising tide lifts all ships, so to speak.
If enough of these health factors reside in a state that either increases or decreases AD pathology
buildup, an individual’s pathology trajectory can be dramatically affected. As a field, the
questions we are left with are: ‘how do we account for all of these factors?’ and ‘what are the
potential benefits to disease management of integrating these factors (i.e. is it worth it?)?’.

9

1.4 Individualized Trajectory Modeling: Can it Work with
AD and what we need to get there
The ability to customize individual patient trajectory modeling with relevant risk modifiers and

sources of pathology variance would give researchers and clinicians a better understanding of the
mechanisms by which pathology progression is happening and allow them to inform patients
with a better idea of how and when their disease will manifest. Aside from these benefits, the
true utility of individual patient modeling comes with the availability and proliferation of
treatment options for reducing and/or delaying AD pathology progression.
The recent successes of stage III trials of anti-amyloid monoclonal antibody therapies
in reducing amyloid load in LOAD and DIAD participants represent the beginning of an era in
which clinicians and researchers may finally have the means to influence the pathological
progression of AD. Several anti-tau antibodies are also in development or in early trial stages,
and offer much promise for affecting this aspect of AD pathology. Potential combination
therapies of anti-amyloid and anti-tau antibodies could offer opportunities to attack the
pathological cascade from multiple angles.
Despite the unprecedented promise of these monoclonal antibody therapies in treating
AD pathology, monoclonal antibody therapies are prohibitively expensive and must be
administered via infusion, which creates further patient burden. With an estimated 6.2 million
individuals aged 65 or older in the United States alone affected by AD, and with that number
only set to increase for the foreseeable future, the scale at which treatment would need to be
administered is immense. Knowing exactly who and when to treat will be vital to overall success
of large-scale therapy delivery.
We will only be able to make decisions about treatment administration at this scale
with detailed disease progression models that account for as many sources of individual
10

pathology variation as possible, are able to translate this information into individual-level
predictions of risk, current and future pathology progression estimations with, and estimated
future effects of treatment and/or lifestyle interventions. This is an incredibly tall order, and will
take numerous advances in our understanding of the disease and revision of our modeling
strategies. However, we can derive key areas where advancements are needed in order to reach
this objective.
First, we need to increase our understanding of sources of individual pathology
variation and how they impact each aspect of pathology progression. In particular, we must focus
on sources with the highest potential for impact on overall disease progression. Second, current
disease progression models have limited ability to provide individual-level insights. Modification
of these modeling strategies to provide more individual-level insights or development of new
strategies that can provide individual predictions and accommodate large amounts of potential
disease modifiers is essential. Third, we need to develop detailed understanding of how state of
the art therapies work mechanistically, and how this translates to pathology trajectory deflection
and symptom modification.
This dissertation seeks to provide valuable contributions in those three key areas.
Chapters 2 and 3 describe work that seeks to extend our understanding of key sources of
pathology variation both from within the pathological cascade and from external factors (Figure
1.3A). Chapter 4 demonstrates proof of concept for using a machine learning based model for
generating individual-level pathology insights and predictions (Figure 1.3B). Chapter 5 seeks to
extend our knowledge of a state-of-the-art disease modifying therapy and how its use affects
pathology levels of both its primary target and other aspects of the pathological cascade (Figure
1.3C).
11

Figure 1.3. Methodology diagram for this dissertation.
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Chapter 2: Examining Concurrent AD
Pathology Buildup and Structural Atrophy
2.1 Cross-Sectional and Longitudinal Atrophy is
Preferentially Associated with Tau rather than Amyloid β
Positron Emission Tomography Pathology (Gordon &
McCullough et al., 2018)
Section 2.1 was taken from previously published first author work105. Structural magnetic

resonance imaging is a marker of gray matter health and decline that is sensitive to impaired
cognition and Alzheimer's disease pathology. Prior work has shown that both amyloid β (Aβ)
and tau biomarkers are related to cortical thinning, but it is unclear what unique influences they
have on the brain. Aβ pathology was measured with [18F] AV-45 (florbetapir) positron emission
tomography (PET) and tau was assessed with [18F] AV-1451 (flortaucipir) PET in a population
of 178 older adults, of which 123 had longitudinal magnetic resonance imaging assessments
(average of 5.7 years) that preceded the PET acquisitions. In cross-sectional analyses, greater tau
PET pathology was associated with thinner cortices. When examined independently in
longitudinal models, both Aβ and tau were associated with greater antecedent loss of gray matter.
However, when examined in a combined model, levels of tau, but not Aβ, were still highly
related to change in cortical thickness. Measures of tau PET are strongly related to gray matter
atrophy and likely mediate relationships between Aβ and gray matter.

2.1.1 Introduction

One of the earliest established and most widely replicated neuroimaging findings in Alzheimer’s
disease (AD) is a reduction in gray matter and greater rates of longitudinal atrophy106–110 seen
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with magnetic resonance imaging (MRI). Similarly, lower baseline levels and greater gray matter
atrophy have been found in participants with mild cognitive impairment111, subjective memory
complaints112, and cognitively normal individuals with abnormal levels of amyloid β
(Aβ)109,110,113–115 relative to those without any AD pathology. In a clinical setting, structural
pathological MRI measures and rates of change have prognostic value, predict conversion from
mild cognitive impairment to AD116–119, and an increased risk of later AD dementia in
cognitively normal individuals120.
While much of the focus has understandably been on the medial temporal lobes, loss of
gray matter is not restricted to these regions. Analyses looking at whole-brain spatial patterns see
loss of gray matter prominently throughout the temporal, parietal, frontal, and occipital
regions108,109,111. Prior work shows that such structural atrophy is related to levels of
Aβ110,115,121,122, but increased levels of Aβ may simply be a proxy for other AD-related
pathologies such as neurofibrillary tangles (NFTs).
Positron emission tomography (PET) ligands that bind to NFTs123–126 have provided a
new biomarker to understand AD. Tau PET is elevated in AD127–133 and in cognitively normal
individuals with elevated Aβ pathology128,130,134,135. Elevated tau PET binding predicts other
neurodegenerative biomarkers such as hypometabolism136–138 and structural atrophy139–141.
Owing to the accessibility and prevalence of structural MRI imaging, it is critical to
understand the relationship between tau PET and gray matter integrity. Prior work has examined
cross-sectional relationships between tau PET using AV-1451 and cortical thickness139–142,
finding that increased levels of tau PET binding were associated with thinner cortices,
particularly in temporal, lateral parietal, and occipital regions. There is also initial evidence that
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prior longitudinal changes in structural MRI over a limited time window (~3 years) predict
current levels of NFT pathology measured with PET140. This cross-sectional and longitudinal
work reveals that there is a clear relationship between in vivo measures of tau pathology and
structural integrity but has only evaluated the influence of tau pathology without also
additionally considering measures of Aβ.
In a population of cognitively normal and mildly impaired older adults, the current work
examines the influence of Aβ and NFT pathology on structural integrity. We examine both the
concurrent relationship between cortical thickness and pathology and the relationship between
current levels of pathology and antecedent longitudinal change in cortical thickness. By
considering both pathologies simultaneously, it is possible to estimate the unique influence each
has on structural atrophy. This is critical not only to understand how tau pathology is related to
another marker of neurodegeneration but also to explore whether tau pathology mediates prior
observed relationships between Aβ and gray matter health.

2.1.2 Methods
Participants

Participants were selected from ongoing studies on aging and dementia from the Knight
Alzheimer’s Disease Research Center at Washington University. Cognitive status was assessed
using the clinical dementia rating (CDR)143. Participants were required to have tau PET imaging
and structural MRI at their most recent neuroimaging assessment. The cross-sectional cohort
consisted of 178 individuals (age 46–91 years) with either no cognitive impairment (n = 156,
CDR = 0) or very mild dementia (n = 22, CDR = 0.5). From this initial population, 123
individuals had at least one MRI session that preceded the acquisition of tau PET (age 55–91
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years; n = 111, CDR = 0; n = 12, CDR = 0.5). Full demographics for the cohort at the time of the
tau PET session are presented in Table 2.1.
Table 2.1. Sample demographics
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MRI acquisition and Processing
T1-weighted images were acquired using a magnetization-prepared rapid gradient-echo sequence
on a 3T Siemens scanner. Scans had a resolution of either 1 × 1 × 1.25 mm or 1 × 1 × 1 mm.
Structural scans were processed with FreeSurfer144. For each hemisphere, cortical thickness
values were obtained for all FreeSurfer cortical regions of interest (ROIs), and volumes were
obtained for all FreeSurfer subcortical ROIs. Cortical thickness was calculated as the shortest
distance between the cortical gray/white boundary and the gray/cerebrospinal fluid (CSF)
boundary145. Cortical surface meshes are placed into a common anatomical space within
FreeSurfer for vertex-wise analyses. Parcellations of the T1-weighted image into cortical and
subcortical regions were also performed for utilization in the processing of PET data.
Longitudinal data were processed through the FreeSurfer 5.3 longitudinal stream146. There was a
total of 390 sessions in the longitudinal analyses (mean 3.1 visits, 5.7 years).
PET Acquisition and Processing
Aβ PET imaging was completed using [18F] AV-45 (florbetapir). Data from the 50- to 70-minute
postinjection window were analyzed using an in-house pipeline using ROIs derived from
FreeSurfer144,147 (PET Unified Pipeline, https://github.com/ysu001/PUP). Tau PET imaging was
performed using [18F] AV-1451 (flortaucipir). Data from the 80- to 100-minute postinjection
window were analyzed. For both tracers, regional estimates were transformed into standardized
uptake value ratios using a cerebellar cortex reference region, although alternate reference
regions are also used in the literature148. Data were partial volume corrected using a regional
spread function technique149,150. This approach corrects for the spillover signal from adjacent
ROIs based upon the scanner point spread function and the relative distance between ROIs. ROI
PET data were averaged across hemispheres for statistical analyses. A summary global Aβ42 and
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tau135 measures were calculated as previously published. On average, PET data were acquired
within 3.6 months of one another.
Statistical Analyses
Cross-sectional vertex-wise analyses were performed using the FreeSurfer Qdec application
(www.surfer.nmr.mgh.harvard.edu). Three statistical models were examined using general linear
models. The first related the summary measure of tau135, as measured with flortaucipir, to vertex
measures of cortical thickness. The second model related the Aβ summary measure, as measured
with florbetapir, to vertex measurements of cortical thickness. Finally, to assess the unique
influence of each pathology, the last model included both the Aβ and tau summary measures. All
three models were run separately for the left and right hemispheres and included current age,
gender, and scan resolution (1 x 1 x 1 or 1 x 1 x 1.25) as covariates. Vertices were considered
significant after a false discovery rate correction considering both hemispheres.
Longitudinal analyses were performed two ways. The first set of analyses examined
relationships of pathology with antecedent longitudinal change in cortical thickness at the
cortical surface level using spatiotemporal linear mixed-effects (LMEs) models119,151
implemented in MATLAB. LMEs are highly flexible approaches for analyzing longitudinal
neuroimaging data because they can handle unequal numbers of data points and temporal
spacing between assessments across subjects. The spatiotemporal approach is an extension of
LMEs for mass-univariate analyses but also takes into account pooled covariance structure
across neighboring vertices of homogenous regions. Three models were again run and were
similar in structure to the cross-sectional models. In the first model, preceding longitudinal
change in cortical thickness was predicted by the main effects of our current tau PET summary
measure, gender, current age, time, scan resolution (1 x 1 x 1 or 1 x 1 x 1.25), and the interaction
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between tau PET and time. Models included random subject-specific slopes and intercepts. The
second model implemented was identical in structure but used Aβ PET rather than tau as a
predictor. The third, combined model examined the main effects and interactions with time of
both global tau and Aβ PET. All three models were implemented separately for the left and right
hemispheres, and vertices were considered significant after surviving false discovery rate
correction accounting for comparisons in both hemispheres.
Finally, a series of LME data were run using ROIs derived from FreeSurfer to examine
the effects of local pathology on local atrophy. Regional data were averaged between left and
right hemispheres. Instead of examining the association between global summaries of Aβ and tau
and cortical thickness, these analyses specifically modeled Aβ and tau PET binding within each
ROI (e.g., precuneus) to thickness in that same ROI. This was done to avoid any bias that could
be introduced by using summary measures formed from specific ROIs. The first model looked at
the relationship between longitudinal measurements of thickness in that ROI predicted by main
effects of current tau in that specific ROI, gender, current age, time, scan resolution, and the time
by tau interaction. Models contained subject-specific random-effects intercepts and slopes.
Similar models were run using Aβ rather than tau PET as a predictor, and finally combined
models including both tau and Aβ and their interactions with time. These three models were run
for all 34 cortical regions identified by FreeSurfer. Models were implemented using the lme4
package in R, version 3.4.1, and ROIs were considered significant after false discovery rate
correction.
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2.1.3 Results

Cross-sectional associations with global pathology
The vertex-wise results are presented in the left-hand column of Fig. 2.1. Fig. 2.1A depicts those
vertices that had a significant relationship with the global tau PET measure. Fig. 2.1B depicts
those vertices significantly related to the global Aβ PET measure. Fig. 2.1C shows those vertices
significantly related to tau while additionally controlling for levels of Aβ. There were no vertices
significantly related to Aβ when entered alone (Fig. 2.1B) or when tau was also included in the
model (not shown). For simplicity, only the results from the left hemisphere are presented.
Results for the right hemisphere are highly similar and presented in Supplementary Fig. 2.1.
Longitudinal associations with global pathology
Results from the spatiotemporal LMEs are presented in the right-hand column of Fig. 2.1. Fig.
2.1D shows those areas of the cortex that showed a significant global tau burden by time
interaction, that is, how current levels of tau predict antecedent thickness change in cortical
thickness. Fig. 2.1E depicts the Aβ by time interaction. Fig. 2.1F shows the tau by time
interaction after additionally controlling for the main effect of global Aβ burden and Aβ by time
interaction. There were no significant Aβ by time effects once tau was simultaneously considered
in the model.
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Fig. 2.1. The relationship between global AD pathology and gray matter. Three GLMs were implemented to
estimate vertex-wise relationships between (A) global tau PET summary measure, (B) Aβ mean cortical SUVR, or
(C) global tau controlling for Aβ, and left-hemisphere cross-sectional cortical thickness. Spatiotemporal LMEs
models were used to investigate relationships between (D) global tau and time from initial MRI, (E) global Aβ and
time, or (F) global tau and time controlling for Aβ and time, and antecedent longitudinal change in cortical
thickness. All models controlled for the main effects of gender, current age, and scan resolution. Cross-sectional
models used the Qdec multiple comparisons correction (FDR) procedure at P < .025 level to approximate
comparisons in both hemispheres. Longitudinal models used the LME FDR2 comparisons correction in MATLAB
and accounted for comparisons in both hemispheres. Values depicted from each model are thresholded at the level
of significance identified by their respective FDR procedures. Abbreviations: Aβ, amyloid β; AD, Alzheimer's
disease; FDR, false discovery rate; GLM, general linear model; LMEs, linear mixed-effects; MRI, magnetic
resonance imaging; PET, positron emission tomography; SUVR, standardized uptake value ratio.
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Longitudinal associations with local pathology
Results examining the relationships between antecedent structural change and local AD
pathologies are shown in Fig. 2.2 and presented in Table 2.2. To be visually consistent with Fig.
1, results are displayed on the left hemisphere but represented the statistical results from the
average of data from left and right hemispheres. Fig. 2.2 depicts the significant regional tau
burden by time interaction (e.g., the relationship between precuneus tau and change in precuneus
cortical thickness). Fig. 2.2B depicts the local Aβ by time interaction. Fig. 2.2C depicts the local
tau by time interaction when both tau and Aβ main effects and interactions were considered in
the model simultaneously. There were no significant associations between local Aβ and change
in cortical thickness once tau was additionally considered in the model.

Fig. 2.2. The relationship between local
AD pathology and gray matter. Linear
mixed-effects models were implemented
to model region-wise relationships
between (A) local tau and time, (B) local
Aβ and time, or (C) local tau and time
controlling for local Aβ and time, on
longitudinal local cortical thickness in all
34 FreeSurfer cortical regions. All
models controlled for the main effects of
gender, age, and scan resolution. Both
hemispheres' values were averaged
together. Values depicted are adjusted
−log10(P) values after FDR correction
for multiple comparisons. Abbreviations:
AD, Alzheimer's disease; FDR, false
discovery rate.
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Table 2.2. Regional effects relating tau and Aβ to longitudinal rates of atrophy
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2.1.4 Discussion

Prior work has demonstrated that structural MRI is a sensitive marker to AD dementia106–110 and
preclinical AD109,110,113–115. The advent of tau PET imaging has provided another in vivo
biomarker of the molecular pathology in AD. The current work examined the association
between cortical thickness and tau pathology measured with flortaucipir PET. We found that
current levels of tau PET binding, rather than Ab PET, were related to concurrent cortical
thinning and preceding structural atrophy.
We found that both global and local levels of florbetapir were associated with greater
antecedent atrophy. This is consistent with prior work in the field demonstrating structural
declines in preclinical AD109,110,113–115. Early work has also indicated a significant relationship
between tau PET binding and gray matter health139–142. When simultaneously considering both
biomarkers, levels of tau PET mediated the effects of Aβ on cortical thickness. This suggests that
in prior work, the association between gray matter and Aβ may have been a proxy for emerging
NFT pathology. This also suggests that the relationship between tau PET and cortical thickness
is distinct from the influence of Aβ.
The association between increasing levels of tau PET and cortical thinning was not
restricted to the medial temporal lobe but was widespread throughout the temporal, occipital,
parietal, and even portions of the frontal lobes. The effects in the temporal and parietal regions
were particularly reminiscent of spatial signatures seen when examining whole-brain atrophy
maps in AD108–110, indicating a stable network of brain regions that also demonstrate tau-related
atrophy. The pattern of areas demonstrating atrophy is also more similar to the spatial
topography of tau rather than Aβ PET127–133,136. This effect was not however simply a product of
the regions going into our summary measures. Analyses looking only at local tau and Aβ
24

accumulation recapitulated similar regional maps, suggesting a stronger local relationship
between structural atrophy and tau than atrophy and Aβ.
The current work and prior results140 indicate that NFT pathology measured with
flortaucipir is related to cross-sectional cortical thinning, as well as atrophy that has occurred
over the previous years. In models of AD pathophysiology152, as well as work with autosomal
dominant AD153, changes in tau pathology occur before structural changes seen with MRI. Such
frameworks would suggest that tau pathology would be a stronger predictor of future rather than
retrospective atrophy. Such a temporal relationship, for example, tau leading MRI with a time
lag, could still account for the current results. For example, we also found that rates of MRI
change were also related to current levels of Aβ, although there is strong evidence that elevations
in Aβ plaque deposition precedes all other pathologies153. Rates of structural atrophy may simply
serve as a rough marker of the disease stage. As a result, greater antecedent atrophy could predict
current Aβ or tau PET, even if that is not the correct causative temporal direction.
Alternatively, the temporal ordering of tau relative to structural MRI has been based on
CSF total tau and phosphorylated tau. Although CSF and PET measures of tau are modestly
correlated128,134,142, these two markers likely measure distinct but related aspects of tau. Just as
there appears to be a temporal lag between CSF and PET measures of Aβ154,155, there is likely a
temporal delay between changes in CSF and PET measures of tau. As a result, tau PET may be
later in disease progression and more proximal or even later to changes seen with structural MRI.
Neuronal dysfunction and reduced dendritic branching may initially occur and manifest on MRI
before mature tangles125 that are bound by flortaucipir form. Prospective acquisition of both
longitudinal MRI and tau PET along with work in autosomal dominant AD populations will help
to clarify the temporal dynamics of tau PET relative to other markers.
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2.1.5 Research in Context
Systematic review

The authors reviewed the literature using traditional sources (e.g. PubMed and Google Scholar)
for articles examining structural decline in preclinical and clinical Alzheimer’s disease as well as
for work using tau positron emission tomography imaging. Although tau positron emission
tomography imaging has been related to neuro- degenerative biomarkers, it is still not understood
how tau pathology relates to cortical atrophy in relation to amyloid b deposition.
Interpretation
Our work found that tau rather than amyloid β predicts concurrent and antecedent gray matter
loss. This result is consistent with neuropathology work indicating that tau pathology is a better
marker of cognitive impairment than amyloid β.
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Future directions
The manuscript found relationships between preceding changes in cortical integrity and current
levels of tau pathology. Future work using longitudinal measures of both tau and magnetic
resonance imaging and will help to further clarify the temporal dynamic between these markers.
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2.1.6 Supplementary Information

Supp. Figure 2.1. Vertex-wise cross-sectional (left) and longitudinal (right) analyses displaying statistical results on
the right hemisphere. Cross-sectionally higher levels of A) tau are associated with lower cortical thickness, and this
remains even when C) controlling for levels of beta-amyloid. Both baseline levels of D) tau and E) beta-amyloid are
associated with preceding rates of atrophy. When examined in a combined model F) tau, but not beta-amyloid is still
significantly related to atrophy rates.
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Supp. Figure 2.2a.

Supp. Figure 2.2b
Supp. Figure 2.2a and 2.2b: Cross-sectional and longitudinal relationships between tau and beta-amyloid and
cortical thickness using a more lenient (p=0.1) statistical threshold. Figure 2a presents the associations for the left
hemisphere while 2b presents the values on the right hemisphere.
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Chapter 3: Prominent Health Factors Affect
Pathology Development in Alzheimer Disease
3.1 Reduced Non-rapid Eye Movement Sleep is Associated
with Tau Pathology in Early Alzheimer’s Disease (Lucey,
McCullough et al., 2019)
Section 3.1 was taken from previously published co-author work156. I was responsible for the

data preparation, design and integration, and execution of all global and regional neuroimaging
analyses, along with figure generation, manuscript preparation, and revision of sections that
pertained to neuroimaging-based analyses.
In Alzheimer’s disease (AD), deposition of insoluble amyloid-β (Aβ) is followed by
intracellular aggregation of tau in the neocortex and subsequent neuronal cell loss, synaptic loss,
brain atrophy, and cognitive impairment. By the time even the earliest clinical symptoms are
detectable, Aβ accumulation is close to reaching its peak and neocortical tau pathology is
frequently already present. The period in which AD pathology is accumulating in the absence of
cognitive symptoms represents a clinically relevant time window for therapeutic intervention.
Sleep is increasingly recognized as a potential marker for AD pathology and future risk of
cognitive impairment. Previous studies in animal models and humans have associated decreased
non–rapid eye movement (NREM) sleep slow wave activity (SWA) with Aβ deposition. In this
study, we analyzed cognitive performance, brain imaging, and cerebrospinal fluid (CSF) AD
biomarkers in participants enrolled in longitudinal studies of aging. In addition, we monitored
their sleep using a single-channel electroencephalography (EEG) device worn on the forehead.
After adjusting for multiple covariates such as age and sex, we found that NREM SWA showed
an inverse relationship with AD pathology, particularly tauopathy, and that this association was
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most evident at the lowest frequencies of NREM SWA. Given that our study participants were
predominantly cognitively normal, this suggested that changes in NREM SWA, especially at 1 to
2 Hz, might be able to discriminate tau pathology and cognitive impairment either before or at
the earliest stages of symptomatic AD.

3.1.1 Introduction

Aggregation of amyloid-β (Aβ) into oligomers and fibrils that are present in extracellular Aβ
plaques in the brain is a key early step in Alzheimer’s disease (AD) pathogenesis and begins to
occur ~15 to 20 years before the onset of cognitive decline157. The buildup of insoluble Aβ is
followed by the intracellular aggregation of tau and its spread from the medial temporal lobe to
different neocortical regions157,158. Localized tau aggregation in the medial temporal lobe during
normal aging is probably independent of Aβ; however, in AD, its spread to the neocortex appears
to be downstream from Aβ buildup and correlates strongly with neuronal cell loss, synaptic loss,
brain atrophy, and cognitive impairment. These findings are strongly supported by genetic,
pathological, and biomarker data in both sporadic and inherited AD157,158. By the time even the
earliest clinical symptoms of AD are detectable, Aβ accumulation is close to reaching its peak,
and there is almost always some neocortical tau pathology159. Aβ42, the isoform of Aβ most
prone to aggregate in insoluble plaques, decreases in cerebrospinal fluid (CSF) with brain
amyloid deposition and correlates with amyloid positron emission tomography (PET)160. The
CSF tau/Aβ42 ratio is related to the dual effect of amyloid and tau pathology and predicts
conversion to early symptomatic AD161–163. There is also neuronal and synaptic loss in several
brain regions relevant to memory and thinking159. The period in which AD pathology is
accumulating in the absence of cognitive symptoms has been termed “preclinical” AD164,165.
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A bidirectional relationship between sleep and AD has been proposed on the basis of
studies in animal models and humans166–168. Numerous studies have shown that sleep-wake
activity is disturbed in individuals with dementia due to AD169,170. Sleep disturbance has been
measured via self-report, such as with questionnaires and sleep logs, as well as actigraphy and
polysomnography. Increasing evidence also supports sleep disturbance as a marker for AD
pathology and future risk of cognitive impairment171–178. For instance, self-reported sleep
disturbances, such as poor sleep quality and short sleep duration, have been associated with
increased risk of cognitive impairment171 and increased Aβ deposition on [11C] Pittsburgh
compound B (PiB) PET scans172. Furthermore, excessive daytime sleepiness reported by a cohort
of older adults was associated with increased longitudinal Aβ accumulation on PiB-PET scans173.
Sleep logs and actigraphy monitoring have found that reduced sleep efficiency and increased nap
frequency in cognitively normal individuals were associated with Aβ deposition174. Studies with
polysomnography have associated increased risk of cognitive impairment in older adults with
sleep-disordered breathing175–177 and periodic limb movements during sleep178.
In addition to sleep disturbance as a putative marker of AD pathology, evidence also
supports the hypothesis that disturbed sleep increases AD risk, at least in part, via an Aβ
mechanism167. We have found that Aβ concentrations in CSF fluctuate with sleep-wake activity
in both mice179 and humans180. This Aβ cycling pattern has been replicated in multiple studies181
and assays182. Aβ concentrations are directly regulated by neuronal activity183–187 and evidence in
mice suggests that decreased interstitial fluid (ISF) during sleep results, at least in part, from
altered neuronal/metabolic activity decreasing Aβ production/release. In humans, we have
recently shown that targeted slow wave sleep disruption188 and sleep deprivation189 will increase
overnight CSF Aβ concentrations by 10 to 30% most likely due to increased Aβ
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production/release. There is also evidence that Aβ clearance is increased during sleep due to
increased ISF bulk flow (for example, “glymphatic” clearance)190–193.
Studies in animal models using electroencephalography (EEG) to monitor different sleep
stages have found changes in sleep parameters and EEG power linked with both Aβ and tau
pathology. For instance, Aβ deposition in APPswe/PS1δE9 mice led to disruption of the sleepwake cycle (35), whereas increasing tauopathy in P301S tau transgenic mice was associated with
decreased time in rapid eye movement (REM) and non-REM (NREM) sleep, increased
wakefulness, and decreased NREM slow wave activity (SWA) (36). In humans, atrophy and Aβ
accumulation in the medial prefrontal cortex (mPFC) were correlated with both decreased
NREM SWA and impaired overnight hippocampus-dependent memory consolidation in
cognitively normal older adults (37, 38). Although that cross-sectional study provides associative
evidence between Aβ deposition, NREM sleep disruption, and memory impairment, tau
pathology was not assessed. Longitudinal studies with AD biomarkers and cognitive evaluations
are needed to establish both the sequential links between these events and causation88, especially
in relation to both Aβ and tau.
In this study, we monitored sleep-wake activity in 119 participants enrolled in
longitudinal studies of aging at the Knight Alzheimer’s Disease Research Center at Washington
University. Sleep-wake activity was monitored over six nights with a single-channel EEG worn
on the forehead (Sleep Profiler, Advanced Brain Monitoring), actigraphy (Actiwatch 2, Philips
Respironics), and sleep logs. In addition, each participant was assessed for sleep-disordered
breathing and periodic leg movements with a home sleep test (Alice PDx, Philips Respironics).
Participants who underwent cognitive testing, apolipoprotein E (ApoE) genotyping, and
assessment of AD biomarkers in CSF [Aβ42, tau, phosphorylated tau (p-tau)] or PET scans with
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[18F] AV-45 (florbetapir) amyloid and [18F] AV-1451 (flortaucipir) tau tracers were included in
the analyses. Because tau pathology, but not Aβ pathology, is best associated with cognitive
decline in AD, we hypothesized that decreased NREM SWA would be associated with increased
tau pathology.

3.1.2 Methods
Study Design

This is an ongoing longitudinal observational study to assess the association between sleep
parameters and the AD biomarkers in which sleep-wake activity was observed over six nights.
All sleep data collected by 3 April 2018 were included in the analysis. One hundred nineteen
participants enrolled in longitudinal studies at the Knight Alzheimer’s Disease Research Center
at Washington University in St. Louis, MO, were recruited thus far to participate in this study.
All participants were >60 years old and assessed clinically with a standard protocol that included
obtaining a CDR, which ranged from 0 (no impairment) to 3 (maximal impairment)195,196.
Participants who completed all assessments were included in the analysis. Of the 38 participants
who completed PET imaging, 29 participants (76.3%) had a score of 0 and 9 participants
(23.7%) had a score of 0.5. These percentages were similar to 104 participants who underwent
lumbar puncture for CSF collection with 79.8% CDR 0 and 20.2% CDR 0.5. ApoE genotype
was obtained from the Knight Alzheimer’s Disease Research Center Genetics Core. Participants
also reported if they were taking any of the following medications that could affect sleep:
benzodiazepine receptor agonists (zolpidem, zaleplon, eszopiclone), benzodiazepines (triazolam,
temazepam, alprazolam), ramelteon, gabapentin, dopamine agonists (ropinirole, pramipexole,
rotigotine), doxepin, antihistamines, antidepressants, and narcotics. Participants were listed as on
a sleep medication if they were taking at least one medication from this list. Participant
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demographic information is shown in Table 3.1. The study protocol was approved by the
Washington University Institutional Review Board. All participants provided written informed
consent and were compensated for their participation in the study.
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Table 3.1 Participant characteristics.
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Sleep Monitoring
Sleep was assessed longitudinally in all participants using three separate measures over six
nights at home: (i) sleep logs, (ii) actigraphy (Actiwatch 2, Philips Respironics), and (iii) a
single-channel EEG device worn on the forehead (Sleep Profiler, Advanced Brain Monitoring).
Sleep logs and actigraphy were scored as previously reported174. Single-channel EEG sleep
studies were visually scored by registered polysomnographic technologists using criteria adapted
from the standard American Academy of Sleep Medicine (AASM) criteria197. Sleep parameters
for time in each sleep stage, sleep latency, sleep efficiency, WASO, and TST were calculated.
Nights were excluded if >10% of the recording was artifactual or if the bed and rise times did not
match the sleep log and/or actigraphy. All participants needed at least two nights from the singlechannel EEG device that met these criteria to be included in this analysis.
Because of the increased prevalence of sleep apnea and periodic leg movements during
sleep with age, all participants were monitored for one night with a home sleep test (Alice PDx,
Philips Respironics). Bed and rise times were confirmed with sleep logs and actigraphy. A
minimum of 4 hours artifact-free recording was obtained for all participants. Respiratory events
and periodic leg movements were scored by registered polysomnographic technologists using
AASM criteria; hypopneas were scored using 4% oxygen desaturation. AHI and PLMI were
calculated per hour of monitoring time for each participant.
Spectral Power Analysis
SWA during NREM sleep was calculated from each single-channel EEG study using Matlab
(MathWorks, Natick, MA), as previously described197–199. To briefly summarize, the EEG signal
was downsampled to 128 Hz for analysis to eliminate processing error. The single-channel EEG
device filtered the signal during acquisition with a 0.1– to 0.6–band-stop filter. We then applied a
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band-pass (two-way least-squares finite impulse response) filter between 0.5 and 40 Hz. Spectral
analysis was performed in consecutive 6-s epochs (Welch method, Hamming window, no
overlap). Artifacts were excluded in a semiautomatic method. Power in the 20- to 30-Hz and 1to 4.5-Hz bands for each electrode across all epochs of a recording was displayed. The operator
(B.P.L.) then selected a threshold between the 95th and 99.5% threshold of power to remove
artifactual epochs. This resulted in fewer than 4% of all epochs being rejected as artifactual.
MRI Acquisition
T1-weighted images were acquired using a magnetization-prepared rapid gradient-echo sequence
on a Siemens Biograph mMR or Tim Trio 3T scanner. Scans had a resolution of either 1 × 1 × 1
mm or 1 × 1 × 1.25 mm. Parcellations of the T1-weighted image into cortical and subcortical
regions were performed with FreeSurfer v5.3-HCP94 for use in the processing of PET data.
PET Acquisition
Thirty-eight participants underwent PET imaging with both amyloid and tau tracers. Amyloid
PET imaging was performed using [18F] AV-45 (florbetapir). Data from the 50- to 70- min postinjection window were analyzed with an in-house pipeline using FreeSurfer-derived ROIs (PET
Unified Pipeline, https://github.com/ysu001/PUP)200,201. Tau PET imaging was completed using
[18F] AV-1451 (flortaucipir). Data from the 80- to 100-min post-injection window were
analyzed. Unprocessed tau PET images were reviewed by a nuclear medicine–trained physician
to evaluate for off-target tracer binding; before analysis, one potential participant with sleep
monitoring and a tau PET scan was excluded because of high bone marrow uptake in the frontal
cortex. Regional signal estimates for both tracers were transformed into SUVRs by using
cerebellar cortex as the reference region. Data were partial volume–corrected using a regional
spread function technique202,203. ROI PET data were presented as the average across hemispheres
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for statistical analysis. For global analyses, summary measures of SUVR 1.19 were used for
amyloid negative/positive on AV-45 amyloid PET201, and summary measures of SUVR 1.22
were used for tau negative/positive on AV-1451 tau PET190.
CSF Biomarkers
CSF was collected under a standardized protocol204. After fasting overnight, participants
underwent a lumbar puncture at 8 a.m. CSF (20 to 30 ml) was collected by gravity drip into a 50ml conical tube using a 22-gauge atraumatic Sprotte spinal needle, gently inverted to disrupt
potential gradient effects, and centrifuged at low speed to pellet any cellular debris. Samples
were aliquoted (500 μl) in polypropylene tubes and stored at −80°C until analysis. CSF Aβ42,
total tau, and p-tau 181 were measured as previously described using an automated
electrochemiluminescence immunoassay (Elecsys on the cobase 601 analyzer, Roche)204,205.
Statistical Analysis
All data were entered into a secure, web-based application designed to support data capture for
research studies [Research Electronic Data Capture (REDCap)]206. Statistical significance for all
analyses was set at P < 0.05. No methods were used to predetermine sample sizes. All serial
sleep monitoring nights were analyzed with general linear mixed models using an unstructured
covariance structure to account for the dependencies among the longitudinal measurements207.
For analyses of the participants who completed PET imaging, AV-45 amyloid and AV-1451 tau
PET SUVR, mean-centered age (mean age 74.8 years), sex, race, CDR, ApoE4 status
(negative/positive), mean-centered AHI (mean AHI 9.8 respiratory events per hour of monitoring
time), mean-centered PLMI (mean PLMI 23.2 leg movements per hour of monitoring time), and
sleep medication (yes/no) were treated as fixed effects. Analyses of participants with CSF were
the same as those with imaging biomarkers, and there were no differences in mean-centered age
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(mean age 74.5 years), mean-centered AHI (mean AHI 9.8 respiratory events per hour of
monitoring time), and mean-centered PLMI (mean PLMI 23 leg movements per hour of
monitoring time). The time covariate was longitudinal sleep monitoring over multiple nights and
was treated as a random effect with random intercepts and slopes used to accommodate
individual variation. The normality assumption was verified through residual plots. Statistical
analyses for mixed models were performed using Statistical Analysis Software (SAS). Regional
analysis of AV-45 amyloid and AV-1451 tau PET was performed using R 3.3.2208 with the same
model except for individual ROI rather than whole-brain composite indices. Bonferroni
correction was used when comparing between multiple brain regions. Differences in sleep
parameters between amyloid-negative/positive and tau-negative/positive groups were determined
by unpaired two-tailed t test.

3.1.3 Results

One hundred nineteen participants aged >60 years old enrolled in longitudinal studies of aging at
the Knight Alzheimer’s Disease Research Center at Washington University in St. Louis, MO,
were recruited for the study. Cognitive performance was evaluated by the Clinical Dementia
Rating (CDR)195,196. Participants also underwent AV-45 amyloid and AV-1451 tau PET imaging
and/or lumbar puncture to measure CSF Aβ42, tau, and p-tau concentrations. Sleep monitoring
was performed for up to six nights with sleep logs, actigraphy, and a single-channel EEG.
Average sleep parameters for participants with PET imaging and CSF biomarkers were not
substantially different between amyloid negative versus amyloid positive, tau negative versus tau
positive, and CDR 0 versus CDR 0.5 groups regardless of modality used to measure sleep-wake
activity (supp. tables 3.1 and 3.2). In participants with PET imaging, REM latency was lower in
amyloid-positive participants (t36 = 2.98, P = 0.005) but longer in CDR 0.5 individuals (t36 =
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−2.49, P = 0.018). Amyloid-positive participants had lower wake after sleep onset (WASO)
measured by actigraphy (t35 = 2.07, P = 0.046), whereas sleep-onset latency measured by
actigraphy was prolonged in CDR 0.5 individuals (t35 = −2.33, P = 0.026). For participants with
CSF, CDR 0.5 individuals were found to have longer REM latency measured by EEG (t104 =
−2.91, P = 0.0044) and longer self-reported total sleep time (TST) (t104 = −2.27, P = 0.025).
When measured by actigraphy, sleep efficiency was decreased (t106 = 3.40, P = 0.0009), sleeponset latency was prolonged (t106 = −3.86, P = 0.0002), and WASO was greater (t106 = −2.68,
P = 0.0086) in CDR 0.5 participants compared to CDR 0.
Thirty-eight participants with AV-45 amyloid and AV-1451 tau PET imaging and 104
participants with CSF Aβ42, tau, and p-tau underwent monitoring with the single-channel EEG
device. Twenty-seven participants had both PET imaging and lumbar punctures. Characteristics
for all participants are provided in Table 3.1. Of the participants with PET imaging, 52.6% (20 of
38) of participants were amyloid and tau negative, with 9 participants amyloid positive but tau
negative and 8 participants positive for both amyloid and tau (Table 3.1). One participant was
found to be tau positive but amyloid negative. Amyloid-negative/positive status was set at a
standardized uptake value ratio (SUVR) of 1.19201, and tau-negative/positive status was set at an
SUVR of 1.22209. Average amyloid and tau burden on PET are shown in Figs. 3.1 and 3.2. For
participants with CSF, previously published cutoffs for amyloid positive (CSF Aβ42 < 1098
pg/ml) and tau positive (CSF tau > 242 pg/ml) were used to define AD pathology204. Of the
participants with CSF, 29.8% were negative for amyloid and tau, 33.7% were amyloid positive
but tau negative, 25.9% were positive for both amyloid and tau, and 10.6% were amyloid
negative but tau positive (Table 3.1).
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Fig 3.1. Mean amyloid pathology for the 38 participants with PET imaging.Mean AV-45 amyloid pathology in (A)
all, (B) amyloid-negative, and (C) amyloid-positive subjects as measured in SUVR units after partial volume
correction using a regional spread function (rsf).

Fig 3.2. Mean tau pathology for the 38 participants with PET imaging.Mean AV-1451 tau pathology in (A) all, (B)
tau-negative, and (C) tau-positive subjects as measured in SUVR units after partial volume correction using a
regional spread function.
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Decreased NREM SWA with increased tauopathy
Multiple factors may affect sleep and/or AD pathology including age, sex, and sleep disorders.
To assess the relationship between NREM SWA and tau pathology, we performed general linear
mixed models of NREM SWA with a mean AV-1451 tau PET composite, age, sex, race, ApoE4
status, CDR, apnea-hypopnea index (AHI), periodic limb movement index (PLMI), and sleep
medications. The composite of the mean AV-1451 tau SUVR was determined from the average
SUVR of the entorhinal cortex, amygdala, lateral occipital, and lateral temporal regions.
As AV-1451 tau SUVR increased, all-night 1- to 4.5-Hz SWA was decreased (Table 3.2).
Because previous work found an inverse relationship between the slowest frequencies and
amyloid deposition in the mPFC210, we tested different frequency ranges (1 to 2 Hz, 2 to 3 Hz,
and 3 to 4 Hz) in this model and found that this inverse relationship between NREM SWA and
tau was maximal in the 1- to 2-Hz range (Table 3.2). In our model, time represents longitudinal
sleep monitoring over multiple nights. Time was not significant in the model (P > 0.05),
supporting previous reports that the EEG power measures are stable with small within-subject
night-to-night variability211,212. Age and sex were also inversely associated with NREM SWA.
These findings are not surprising given the well-described decline in NREM SWA with
increased age and male sex213,214. CDR showed negative association with 1- to 2-Hz NREM
SWA, indicating that 1- to 2-Hz NREM SWA decreased with worsening tau pathology and
cognitive impairment.
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Table 3.2. Relationship of NREM SWA to AV-1451 tau PET composite after adjusting for age, sex, race, CDR,
ApoE4 status, AHI, PLMI, sleep medications, and time. Linear mixed models were used to calculate the estimates
and P values for the 38 participants with PET imaging. Time, longitudinal sleep monitoring.
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To investigate how regional differences in AV-1451 tau PET were associated with
NREM SWA, we performed general linear mixed modeling for NREM SWA in frequency
ranges of 1 to 4.5 Hz, 1 to 2 Hz, 2 to 3 Hz, and 3 to 4 Hz with each region of interest (ROI).
Whereas decreased NREM SWA at all slow wave frequencies was associated with
increased tau pathology measured by the AV-1451 tau PET composite, regional analyses,
uncorrected for multiple comparisons, found that this relationship was most evident in the
entorhinal, parahippocampal, inferior parietal, insula, isthmus cingulate, lingual, supramarginal,
and orbitofrontal regions (supp. table 3.3 and supp. fig. 3.1). After correcting for multiple
comparisons, multiple regions on AV-1451 tau PET remained significant for 1- to 4.5-Hz NREM
SWA including the entorhinal, parahippocampal, orbital frontal, precuneus, inferior parietal, and
inferior temporal regions (all P < 0.05; see Fig. 3.3 and supp. table 3.3). This relationship was
driven by 1- to 2-Hz NREM SWA, with only the lingual and medial orbital frontal regions on
AV-1451 tau PET significantly associated with 2- to 3-Hz and 3- to 4-Hz NREM SWA (all P <
0.05). The significance map for 1- to 2-Hz NREM SWA (Fig. 3.3) shows a similar spatial pattern
of tauopathy seen for other changes in AD, such as cortical thickness190–193.
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Fig 3.3. Regional differences in the relationship between NREM SWA and tau PET.
Regional differences in NREM SWA at 1 to 4.5 Hz (A), 1 to 2 Hz (B), 2 to 3 Hz (C), and 3 to 4 Hz (D) on AV-1451
tau PET after correction for multiple comparisons for the 38 participants with PET imaging. Linear mixed models
were performed with NREM SWA as dependent variable and covariates age, sex, race, CDR, ApoE4 status, AHI,
PLMI, sleep medications, and time. Each AV-1451 tau PET region was included in the model individually and was
corrected for multiple comparisons. The P value in the model from each region was mapped on a brain image and
transformed to a logarithmic scale (P < 0.05 = >1.30).
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Decreased 1- to 2-Hz NREM SWA with increased Aβ deposition
Using the same model as for AV-1451 tau PET, we assessed the relationship between NREM
SWA and AV-45 amyloid PET. The mean cortical AV-45 amyloid composite was calculated as
the average SUVR for the frontal, temporal, and parietal lobes. All-night 1- to 4.5-Hz SWA was
not associated with AV-45 amyloid PET (Table 3.3). Then, we tested NREM SWA in frequency
ranges of 1 to 2 Hz, 2 to 3 Hz, and 3 to 4 Hz. There was an inverse relationship between 1- to 2Hz NREM SWA and the mean cortical AV-45 amyloid composite (P = 0.043; Table 3.3).
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Table 3.3. Relationship of NREM SWA to AV-45 amyloid PET composite after adjusting for age, sex, race, CDR,
ApoE4 status, AHI, PLMI, sleep medications, and time. Linear mixed models were used to calculate the estimates
and P values for the 38 participants with PET imaging.
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Uncorrected for multiple comparisons, decreased NREM SWA at 1 to 4.5 Hz and 1 to 2
Hz was associated with increased Aβ deposition in frontal, temporal, and inferior parietal
regions, as well as the supramarginal and isthmus cingulate regions (supp. table 3.4 and supp.
fig. 3.2). At 2 to 3 Hz and 3 to 4 Hz, however, this inverse association with Aβ deposition was
seen in fewer regions including the inferior parietal, isthmus cingulate, transtemporal,
supramarginal, middle frontal, and pars opercularis regions (supp. table 3.4 and supp. fig. 3.2).
After correcting for multiple comparisons, there were no regions on AV-45 amyloid PET
associated with NREM SWA (supp. table 3.4).
Decreased NREM SWA linked with increased CSF tau/Aβ42 ratio but not CSF Aβ42
To further assess the relationship between NREM SWA and AD pathology, we analyzed 23
participants with CSF in the same model used in participants with PET imaging except CSF
Aβ42 and tau/Aβ42 measurements were used as covariates in place of AV-45 amyloid PET and
AV-1451 tau PET, respectively. NREM SWA did not correlate with Aβ42 after adjusting for all
covariates, whereas CDR, race, ApoE4 status, and sleep medications showed correlation with
Aβ42 (Table 3.4).
Previous work found that tau/Aβ42 ratio is sensitive to early stages of AD pathology and
predicts cognitive decline from normal to impaired over several years161–163. Furthermore, poor
sleep has been associated with higher tau/Aβ42 ratio215. Tau/Aβ42 ratio also controls for the
relationship between Aβ42 and tau. In the same model used to investigate the relationship
between NREM SWA and tau PET, there was a significant inverse association between NREM
SWA and tau/Aβ42 (P < 0.05; Table 3.5), indicating that NREM SWA decreased as the
tau/Aβ42 ratio increased (meaning greater AD pathology). CSF tau is a marker of neuronal
injury, and CSF p-tau is a marker for neurofibrillary tangles216; therefore, we also tested the same
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model with p-tau/Aβ42 ratio and found a similar inverse relationship with NREM SWA as
tau/Aβ42 (supp. table 3.5). Similar to our findings for tau PET, the relationships between NREM
SWA and both tau/Aβ42 and p-tau/Aβ42 ratios were maximal at the lowest 1- to 2-Hz
frequencies. CDR, race, ApoE4 status, and sleep medications were also significantly associated
with NREM SWA in the model (all P < 0.05; Table 3.5).
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Table 3.4. Relationship of NREM SWA to A42 after adjusting for age, sex, race, CDR, ApoE4 status, AHI, PLMI,
sleep medications, and time. Linear mixed models were used to calculate the estimates and P values for the 23
participants with CSF.

51

Table 3.5. Relationship of NREM SWA to tau/A42 ratio after adjusting for age, sex, race, CDR, ApoE4 status,
AHI, PLMI, sleep medications, and time. Linear mixed models were used to calculate the estimates and P values for
the 23 participants with CSF.
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Specific sleep parameters associated with AD pathology
Previous studies have shown a relationship between various sleep parameters and AD
pathology172–174,215. To investigate the relationship between other sleep parameters in our model,
we compared the relationship between sleep parameters measured by the single-channel EEG
device, actigraphy, and sleep logs to the mean AV-45 amyloid and AV-1451 tau composites
using the same linear mixed model as above (supp. table 3.6). Sleep parameters tested in the
models included TST, sleep efficiency, sleep latency, REM onset latency, WASO, time in each
sleep stage, number of arousals, and time spent napping per day (supp. table 3.6). No sleep
parameters measured by sleep log or actigraphy were associated with AV-45 amyloid PET. For
EEG-derived sleep parameters, REM latency (F1,30 = 12.5, P = 0.001) and sleep latency (F1,29
= 4.4, P = 0.045) had significant negative relationships with Aβ, suggesting that as Aβ deposition
increased, the time to fall asleep and enter REM sleep decreased.
TST measured by single-channel EEG device (F1,28 = 5.99, P = 0.021) and sleep log
(F1,29 = 4.80, P = 0.037) was positively associated with increased tauopathy in tau PET. That is,
participants slept longer with increased tauopathy. Self-reported time napping on sleep logs was
increased with greater tau pathology (F1,27 = 9.28, P = 0.005) (supp. table 3.6). This suggests
that participants with greater tau pathology experienced daytime sleepiness despite increased
TST. All other sleep parameters measured by EEG, actigraphy, and sleep log did not show
correlation with tauopathy. Using the same model, no sleep parameters measured by EEG,
actigraphy, or sleep log were associated with CSF tau/Aβ42 (supp. table 3.7).

3.1.4 Discussion

Our study showed that NREM SWA has an inverse relationship with AD pathology measured

by PET imaging and CSF biomarkers. That is, NREM SWA decreased with increased evidence
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of Aβ deposition and tau accumulation. For PET, this relationship was stronger with tau than
with Aβ pathology. We also showed that increased CSF tau/Aβ42 ratio, another marker of AD
pathology, was inversely associated with NREM SWA. We observed these associations after
adjustment for multiple potential confounders, particularly age, sex, and CDR, supporting a
strong relationship independent of these factors. Although AV-45 amyloid PET showed a similar
inverse relationship with NREM SWA as AV-1451 tau PET, the estimated magnitude of this
association was greater for tau and the findings with CSF tau/Aβ42 suggest that tau is critical for
this relationship. Because the study participants were predominantly cognitively normal with the
remaining showing only very mild impairment, this suggests that decreased NREM SWA,
especially at the lowest 1- to 2-Hz frequencies, might be associated with tau pathology either
before or at the earliest stages of cognitive decline.
Regional analyses of the PET images found that decreases in NREM SWA were most
pronounced with Aβ deposition in areas of the frontal, temporal, and parietal lobes. There was no
association in our models between NREM SWA and CSF Aβ42. Previous findings associated
decreased NREM SWA, particularly at the lowest 0.6- to 1-Hz frequencies, with Aβ deposition
in the mPFC on PiB-PET imaging210. Because we recorded a single-channel EEG from the
forehead, we were unable to localize the NREM SWA more specifically than to the frontal lobes.
This location of electrode placement likely contributes to the robust relationship between NREM
SWA and tau pathology in the frontal regions. We were also unable to test frequencies in the 0.6to 1-Hz range due to hardware limitation of the single-channel EEG device197. Another recent
study reported associations between baseline excessive daytime sleepiness and longitudinal Aβ
deposition in the anterior cingulate, posterior cingulate-precuneus, and parietal regions173. After
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correcting for multiple comparisons, our study found no association between 1- to 2-Hz SWA
and Aβ deposition in all brain regions analyzed.
For AV-1451 tau PET, regions known to be involved with AD progression showed
associations with decreased NREM SWA including the orbitofrontal, entorhinal,
parahippocampal, lingual, and inferior parietal regions. These relationships were most evident in
the 1- to 2-Hz range, and the association remained valid after correcting for multiple
comparisons. This spatial pattern is similar to other imaging changes in AD, such as cortical
thickness191–193. Decreased cortical thickness, however, does not explain our findings because the
PET ROIs were volume corrected.
We were also able to compare the relationship between PET imaging with AV-45
amyloid and AV-1451 tau tracers, as well as CSF Aβ42 and tau/Aβ42, to sleep parameters
measured with different methods such as sleep logs. Although NREM SWA was associated with
AD pathology, traditional sleep parameters measured by single-channel EEG-based sleep
scoring, actigraphy, or sleep logs generally did not show association in our study. SWA is a
measure of sleep homeostasis and may be altered even when other sleep parameters are
unchanged217. Increased TST measured by the single-channel EEG and sleep log were associated
with increasing tau pathology on PET, as was self-reported increased time napping. These
results, coupled with the NREM SWA findings, suggest that the quality of sleep decreases with
increasing tau despite increased sleep time. Furthermore, self-reported napping time per day may
be an important question to screen individuals for tauopathy.
A strength of our study is the multiple modalities of both sleep monitoring and
biomarkers for AD pathology available from all of our participants. In addition to PET imaging,
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CSF biomarkers, and different sleep measures, we were able to adjust for multiple variables that
affect sleep and AD pathology. Model covariates, such as sex, race, ApoE4, and sleep
medications, need further study in other larger cohorts and longitudinal studies. A weakness of
this study, however, is that we cannot establish whether or not sleep disturbances preceded or
followed the development of AD pathology. Furthermore, this study included only 38
participants in the imaging analyses, and therefore, a limitation of these analyses is overfitting a
model with 10 covariates. Another limitation of our study is that stages of AD pathology (for
example, amyloid negative/tau negative) differed between participants with PET imaging and
CSF. These limitations are offset by the complementary findings between NREM SWA and AD
pathology with both PET imaging and CSF biomarkers. Previous work that reported these
associations between sleep parameters and AD pathology generally included larger numbers of
participants than our study. However, the fact that we could see robust differences in NREM
SWA in relation to tau pathology measured on tau PET and CSF tau/Aβ42 suggests strong
relationships between the variables analyzed.
With the rising incidence of AD in an aging population, our findings have potential
application in both clinical trials and patient screening for AD to noninvasively monitor for
progression of AD pathology. For instance, periodically measuring NREM SWA, in conjunction
with other biomarkers, may have utility monitoring AD risk or response to an AD treatment. To
apply our findings in these settings, further longitudinal studies are needed to confirm the timing
of when NREM SWA decreases in relation to increased Aβ deposition and tauopathy.
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3.1.5 Supplementary Information

Supp. Figure 3.1. Relationship between NREM SWA and tau PET varies by region when uncorrected for
multiple comparisons. For the 38 participants with PET imaging, uncorrected regional differences in frontal
NREM SWA at 1-4.5 Hz (A), 1-2 Hz (B), 2-3 Hz (C), and 3-4 Hz (D) on AV-1451 tau PET. Linear mixed models
were performed with NREM SWA as dependent variable and covariates age, sex, race, CDR, ApoE4 status, AHI,
PLMI, sleep medications, and time. Each AV-1451 tau PET region was included in the model individually and was
not corrected for multiple comparisons. The p-value in the model from each region was mapped on a brain image
and transformed to a logarithmic scale (p<0.05 = >1.30).

Supp. Figure 3.2. Relationship between NREM SWA and amyloid PET varies by region when uncorrected
for multiple comparisons. For the 38 participants with PET imaging, uncorrected regional differences in NREM
SWA at 1-4.5 Hz (A), 1-2 Hz (B), 2-3 Hz (C), and 3-4 Hz (D) on AV45 amyloid PET. Linear mixed models were
performed with NREM SWA as dependent variable and covariates age, sex, race, CDR, ApoE4 status, AHI, PLMI,
sleep medications, and time. Each AV-45 amyloid PET region was included in the model individually and was not
corrected for multiple comparisons. The p-value in the model from each region was mapped on a brain image and
transformed to a logarithmic scale (p<0.05 = >1.30).
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Supp. Table 3.1. Group differences in average sleep parameters between amyloid negative/positive, tau
negative/positive, and CDR 0/0.5 for participants with PET imaging.
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Supp. Table 3.2. Group differences in average sleep parameters between amyloid negative/positive, tau
negative/positive, and CDR 0/0.5 for participants with CSF.
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Supp. Table 3.3. Relationship of NREM SWA power to AV-1451 tau PET regions after adjusting for age, sex, race, CDR, ApoE4 status, AHI, PLMI,
sleep medications, and time.
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Supp. Table 3.4. Relationship of NREM SWA to AV-45 amyloid PET regions after adjusting for age, sex, race, CDR, ApoE4 status, AHI, PLMI, sleep
medications, and time.
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Supp. Table 3.5. Relationship of NREM SWA to p-tau/Aβ42 ratio after adjusting for age, sex, race,
CDR, ApoE4 status, AHI, PLMI, sleep medications, and time.
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Supp. Table 3.6. Relationship of sleep parameters to AV-45 amyloid and AV-1451 tau PET after
adjusting for age, sex, race, CDR, ApoE4 status, AHI, PLMI, sleep medications, and time.
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Supp. Table 3.7. Relationship of sleep parameters to tau/Aβ42 ratio after adjusting for age, sex, race,
CDR, ApoE4 status, AHI, PLMI, sleep medications, and time.
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3.2 Complex Relationship between Body Mass Index and
Cortical Amyloid-β Burden in Late-Life (Thirunavu,
McCullough et al., 2019)

Section 3.2 was taken from previously published co-author work218. I worked extensively on the
data collection, experimental design, and execution of analyses along with contributing to
manuscript creation and revision.
Both low and high body mass index (BMI) have been associated with an increased
risk of dementia, including that caused by Alzheimer’s disease (AD). Specifically, high middleage BMI or a low late-age BMI has been considered a predictor for the development of AD
dementia. Less studied is the relationship between BMI and AD pathology. We explored the
association between BMI and cortical amyloid-β (Aβ) burden in cognitively normal participants
that were either in mid-life (45–60 years) or late-life (>60). We analyzed cross-sectional baseline
data from the Knight Alzheimer Disease Research Center (ADRC) at Washington University. Aβ
pathology was measured in 373 individuals with Aβ PET imaging and was quantified using
Centiloid units. We split the cohort into mid- and late-life groups for analyses (n = 96 and n = 277,
respectively). We ran general linear regression models to predict Aβ levels from BMI while
controlling for age, sex, years of education, and APOE4 status. Analyses were also conducted to
test the interaction between BMI and APOE4 genotype and between BMI and sex. Higher BMI
was associated with lower cortical Aβ burden in late-life (β= –0.81, p = 0.0066), but no
relationship was found in mid-life (β= 0.04, p > 0.5). The BMI×APOE4+ and BMI×male
interaction terms were not significant in the mid-life (β= 0.28, p = 0.41; β= 0.64, p = 0.13) or the
late-life (β= 0.17, p > 0.5; β= 0.50, p = 0.43) groups. Higher late-life BMI is associated with lower
cortical Aβ burden in cognitively normal individuals.
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3.2.1 Introduction

Alzheimer’s disease (AD) is a debilitating, progressive neurodegenerative disease that is the
leading cause of dementia in the United States 219,220. The disease disproportionately affects the
population aged 65 and older. Roughly 96% of total AD cases in the U.S. fall within this age
group 221. As the number of 65+ individuals in the U.S. is projected to increase from 53 million
to 88 million by 2050, the number of Americans with AD will rapidly escalate 222. Given that
$277 billion was spent on AD in 2017 223, it is imperative that risk factors are identified in
cognitively normal populations to better understand how disease progression might be controlled
and to minimize future AD-related healthcare expenditures. Obesity, like AD, also poses a
significant public health problem in the U.S. One in five Americans are morbidly obese, and
obesity itself has been linked with an increased risk of diabetes, coronary heart disease, and
cancer 224. Although higher body mass index (BMI) is generally associated with adverse health
outcomes 225,226, there is evidence that large body size is actually beneficial for those with certain
chronic cardiovascular, pulmonary, and renal diseases 227. These counterintuitive findings also
appear in studies examining the relationship between obesity and dementia 228–233.
Generally, epidemiological studies show that being overweight increases the risk
228,229

of developing a dementing disorder (vascular, AD, etc.). However, there has also been

research showing no increased risk of dementia 230–232 or even a reduced risk of dementia 233.
When examining AD specifically, epidemiological work has shown being overweight is both
associated with an increased risk 234,235 and a decreased risk 227,236–238. These inconsistent findings
relating obesity to an increased risk of dementia may arise from the heterogeneous nature of the
populations being studied. Specifically, the obesity-dementia relationship seems to differ for
those in mid-life versus late-life 228,239–244, and this difference may be attributed to weight loss
occurring near the onset of dementia 243,244 or a long preclinical phase that is associated with
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weight loss, sarcopenia, and fat mass reduction 245–250. Due to these findings, it is imperative to
study the obesity-dementia relationship separately for each age group within a cognitively
normal cohort.
Prior work has primarily focused on how obesity impacts the risk of developing
dementia. As a result, it is unclear if changes in obesity directly impact AD pathology, or instead
just represent co-morbid processes that impact cognition directly. Animal work suggests that
obesity and diabetes can directly influence the accumulation of AD pathology 251–256. In humans,
only a modest number of studies have directly examined the relationship between obesity
measured with BMI and AD pathology 243,257–262 using biomarkers such as cerebrospinal fluid
(CSF) amyloid-β (Aβ) 1–42 261, CSF total tau 258, and cortical Aβ as measured by positron
emission tomography 257,262. These studies have found an association between a greater weight
and lower AD pathology. While this prior work has been informative, these studies typically
have small sample sizes or do not take into the account both how the relationship of BMI on AD
pathology may vary as a function of both age group and APOE4 genotype, the latter of which
has been shown to modify the AD-body composition relationship 257,258.
We sought to further characterize the relationships between obesity and AD by
examining the cross-sectional relationship between BMI and cortical Aβ burden as measured by
PET in cognitively normal (CN) participants. We examined the relationship between weight and
AD pathology in both those in mid-life (45–60 years) and late life (>60) in a cross-sectional
cohort. Based upon prior work, we hypothesized that in CN mid-life individuals, higher BMI
will be associated with elevated cortical Aβ burden. In CN late-life individuals, we hypothesized
that higher BMI will be associated with lower cortical Aβ burden. Additionally, we were
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interested in whether the BMI-Aβ relationship is modified by the presence of an APOE ɛ4 allele
or by sex.

3.2.2 Methods
Participants

Participants were selected from ongoing longitudinal studies of aging and dementia from the
Knight Alzheimer Disease Research Center (ADRC) at Washington University in St. Louis.
Cognitive status in these participants was assessed using the clinical dementia rating (CDR)195.
Participants were required to be clinically normal (CDR = 0), have an Aβ PET scan, have
information on demographic variables (age, sex, and education), have information on APOE
genotype, and have a recorded height and weight (to calculate BMI) from the day of their scan.
Participants were classified as being mid-life (45–60 years) and late-life (>60 years).
Imaging acquisition and processing
Magnetic resonance imaging (MRI) scans were obtained using 3 Tesla volumetric T1-weighted
MRI scanners following the ADNI protocol (http://adni.loni.usc.edu/methods/documents/mriprotocols/) and processed through FreeSurfer, version 5.3200 (Martinos Center, Boston, MA), as
previously described201. The T1-weighted images were used for measurements of hippocampal
volumes adjusted for total intracranial volumes using a regression approach, and for
measurements of cortical volumes and ventricular volumes.
Aβ PET imaging was completed using two tracers: [18F] florbetapir (AV-45, n = 18)
and [11C]- Pittsburgh Compound B (PiB, n = 355). Data were analyzed with an in-house pipeline
using regions of interest (ROIs) derived from FreeSurfer 5.3 segmentations201. Standardized
Uptake Value ratios (SUVRs) were calculated for the time windows between 50–70 min postinjection for AV45 and 30–60 min post-injection for PiB using cerebellar cortex as a reference
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region. Partial volume effects were corrected for using a regional spread function (RSF)
technique203,263.
To assess global Aβ burden, the arithmetic mean of SUVRs from the Freesurfer ROIs
in the prefrontal cortex, precuneus, gyrus rectus, and lateral temporal regions were calculated as
the mean cortical SUVR (MCSUVR), as previously published201. To combine the data from both
tracers, partial volume corrected SUVRs were converted into Centiloid units264,265. A value of 0
on the scale represents the mean Aβ burden of a young control group with no Aβ pathology. A
value of 100 represents the mean Aβ burden of an AD group265.
The equations to convert AV45 and PiB MCSUVRRSF to Centiloid Units derived at
our center are:
53.6 × 𝐴𝐴𝐴𝐴45 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 − 43.2 = 𝐶𝐶𝑒𝑒𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈
Body mass index

45 × 𝑃𝑃𝑃𝑃𝑃𝑃 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 − 47.5 = 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈𝑈

Each participant had a height and weight measurement taken the day of their PET scan. The
standard formula for calculating BMI as defined by the NIH was used to transform height and
weight into participant BMI266. As it is common to examine categorical groupings for additional
analyses, we investigated the BMI-Aβ relationship using BMI subdivisions rather than a
continuous value of BMI. The subdivisions were defined using current NIH guidelines:
underweight (BMI <18.5), normal (BMI 18.5–24.9), overweight (BMI 25–29.9), and obese
(BMI >30). The underweight subdivision was not used for additional analyses as there were too
few individuals in this group (n = 5).
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APOE genotype
DNA was extracted from peripheral blood samples using standard procedures, as previously
described267. APOE4 carrier status was determined by having at least one APOE4 allele.
Statistical analyses
Statistical analyses were performed in R, version 3.5.1. Separate general linear regression models
(GLMs) incorporated continuous measures of BMI and cortical Aβ burden (measured in
Centiloid units). Primary models included the main effect of BMI, age group (mid-life/late-life),
an interaction term of BMI and age group as well as covariates for APOE4 carrier status, sex,
age, and education. Additional linear regressions were run separately for each age group while
including a main effect of BMI and all covariates. Partial regression plots were used to take into
account the effect of multiple independent variables.
Although BMI is continuous, it is often conceptualized as an ordinal measure. For
additional analyses, we investigated the differences in mean cortical Aβ burden between BMI
groups (normal, overweight, obese) by computing a one-way analysis of variance (ANOVA)
testing whether there was a main effect of BMI group on Aβ level followed by a multiple
pairwise-comparison t-test between the means of the BMI groups.
As prior work suggests an interaction between BMI and APOE genotype, we also
investigated the association of continuous measures of BMI and cortical Aβ burden by including
an interaction term for continuous BMI and APOE4 status within each age group.
Finally, we also investigated the interaction between BMI and sex by including an
interaction term for continuous BMI and sex within each age group.
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3.2.3 Results

Baseline characteristics
Based upon the selection criteria, all participants were CN (global CDR = 0). Those in mid-life
(n = 96) were on average 53.5 years of age (range: 45–60), college educated (mean: 16.3 years of
education), 72.9% female, 35.4% had at least one APOE4 allele (E4+). Those in mid-life had a
mean Mini-Mental State Examination score of 28.9 and a mean CDR sum of boxes (CDR-SOB)
of 0.0053. Those in late-life (n = 277) were on average 71.4 years of age (range: 61–100), college
educated (mean: 15.8 years of education), 59.9% female, and 28.5% E4+. Those in late-life had a
mean MMSE score of 28.8 and a mean CDR-SOB of 0.033 (see Table 3.6 for demographics). In
both the mid- and late-life groups, the majority of participants were overweight or obese (64.6%
and 59.6%, respectively). Due to the small number of underweight participants in both groups,
underweight participants were excluded in analyses investigating BMI subdivisions given the
lack of power. APOE4 carrier status, education, age, and other baseline characteristics were not
significantly different between BMI subdivisions in either the mid- or late-life groups as assessed
by t-tests.
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Table 3.6. Demographics of Knight ADRC cohorts with Aβ PET
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Continuous BMI and cortical Aβ burden in mid- and late-life
The relationship between a continuous measure of BMI and cortical Aβ burden is presented in
Fig. 3.4. When modeling an interaction between BMI and age group for the whole cohort, the
BMI×age-group interaction term was significant (p = 0.0309). Thus, there is a differential effect
of BMI in mid-life versus late-life. In the late-life cohort, higher BMI was associated with a
lower cortical Aβ burden (β= –0.82, p = 0.0074) in the linear regression model after including age,
sex, years of education, and APOE4 carrier status. BMI in the mid-life cohort did not show any
significant association with cortical Aβ burden (β= 0.03, p > 0.5) after adjusting for the same
variables (Fig. 3.5). These results remained the same after excluding the four individuals with
highest BMI. The main effect of APOE4 carrier status was significant in both the mid- and latelife models, (β= 6.1, p = 0.0012 and β= 18.1, p < 0.001, respectively), with APOE4 carriers having
elevated cortical Aβ burden compared to non-carriers. Age was also significant in both the midand late-life models (β= 0.51, p = 0.0283 and β= 0.90, p < 0.001, respectively), with higher age
being associated with elevated cortical Aβ burden.
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Fig 3.4. Scatter plot of BMI and cortical Aβ
burden by age group. The scatter plot reflects
raw values for ease of interpretation. Late-life
participants are dark circles, and mid-life
participants are grey triangles. Lines of best fit
are also shown.

Fig 3.5. Partial regression plot from primary
analysis of BMI and cortical Aβ burden (as
measured in Centiloid units) in mid- and latelife individuals. The model was adjusted for
age, sex, years of education, and APOE4 carrier
status. Standardized residuals for Centiloid
units were calculated after regressing cortical
Aβ burden against all the independent variables
except BMI while standardized residuals for
BMI were calculated after regressing BMI
against the remaining independent variables.
BMI was significant in the late-life model but
not the mid-life model. These results remained
the same even after exclusion of the four
individuals with highest BMI.
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Differences in cortical Aβ burden by BMI group in mid- and late-life
To test group differences in mean cortical Aβ burden between the three BMI groups (normal,
overweight, and obese) in mid- or late-life, we computed a one-way ANOVA test examining the
main effect of BMI group separately for the late-life and mid-life cohorts. The ANOVAs showed
that there was a significant difference in the mean cortical Aβ burden between BMI groups in
late-life (F2,269 = 5.60, p = 0.0042). Pairwise-comparison t-tests show a significant difference in
mean cortical Aβ burden between the normal and obese groups in late-life (p < 0.001) (Fig.
3.6A). The mean cortical Aβ burden of the overweight group was not significantly different from
that of the normal group (p = 0.0763) or the obese group (p = 0.0616) in late-life (Fig. 3.6A).
There was no significant main effect of BMI group on Aβ burden in mid-life (F2,93 = 0.069,
p > 0.5). Even in the pair-wise contrasts, there were no significant differences between any BMI
groups in mid-life (Fig. 3.6B), with p > 0.5 for all three comparisons.

Figure 3.6. Boxplots of the distributions of cortical Aβ burden in each of the three BMI groups in late-life (A) and
mid-life (B) individuals. Pairwise comparisons are denoted as N.S. p > 0.05 and ***p < 0.001.
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We then utilized a general linear regression model for late-life participants with
categorical BMI and controlled for age, sex, years of education, and APOE4 status. Compared to
a normal BMI, being classified as overweight or obese was significantly associated with a lower
cortical Aβ burden (β= –7.7, p = 0.0499 and β= –12.4, p = 0.0033, respectively). E4+ and age both
remained significant in the model with categorical BMI for late-life (β= 17.8, p < 0.001 & β= 0.87,
p < 0.001, respectively).
Although by definition sorting individuals into BMI groups limits the ranges values can
take, prior work257 examined whether there was a significant effect of continuous BMI levels
within the different BMI categories. Therefore, we also tested the association between
continuous BMI and cortical Aβ burden within the three BMI categories in late-life individuals
while controlling for age, sex, years of education, and APOE4 status. We found no significant
association between continuous BMI and cortical Aβ burden in any of these groups (normal: β= –
0.42, p > 0.5; overweight: β= –0.19, p > 0.5; obese: β= –0.03, p > 0.5).
Differences in cortical Aβ burden by APOE4 group in mid- and late-life
Additional models for the mid-life and late-life participants added a continuous BMI×APOE4+
interaction term to the primary model (from Fig. 3.4) in order to evaluate if there is a differential
effect of BMI in APOE4 carriers versus non-carriers. This interaction term was not significant in
the mid-life (β= 0.33, p = 0.296) or the late-life (β= 0.29, p > 0.5) groups (Fig. 3.7). As expected,
age remained significant in both the mid-life (β= 0.50, p = 0.035) and late-life (β= 0.89, p < 0.001)
models with the interaction term.
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Figure 3.7. Scatterplot of BMI and cortical Aβ burden within APOE4 subdivisions in mid-life (A) and late-life (B).
The scatter plots reflect raw values for ease of interpretation. E4 non-carriers are black circles, and E4 carriers are
grey triangles. Lines of best fit are also shown. The BMI×APOE4 interaction term was not significant in the mid-life
(β= 0.33, p = 0.296) or the late-life (β= 0.29, p > 0.5) groups.

Differences in cortical Aβ burden by sex in mid- and late-life
Additional models for the mid-life and late-life participants added a continuous BMI×male
interaction term to the primary model (from Fig. 3.4) in order to evaluate if there is a differential
effect of BMI in males versus females. This interaction term was not significant in the mid-life
(β= 0.64, p = 0.13) or the late-life (β= 0.50, p = 0.43) groups. A summary of the additional analyses
can be seen in table 3.7.
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Table 3.7. Summary of additional analyses. All models adjusted for age (or age group), sex, years of education, and
APOE4 status.

Total hippocampal volume
We also ran a general linear regression model assessing the relationship between continuous
BMI and total hippocampal volume. The models were adjusted for the same covariates as in the
Aβ analysis. We found no relationship between continuous BMI and total hippocampal volume
in either the mid-life (β= –11.99, p = 0.46). or late-life (β= 4.0, p > 0.5) groups.

3.2.4 Discussion

A high percentage of adults in Western countries are overweight or obese, just as 61% of the
total cohort in this study was overweight or obese. Trends indicate that the percentages of adults
in these categories will only increase in coming years268. The rising prevalence of obesity has the
potential to have important implications for the cognitive health of adults in different stages of
life. Prior work suggested there might be a relationship between obesity and the risk for
developing dementia. In our analyses, we examined whether a cross-sectional relationship
existed between cortical Aβ burden, a biomarker reflective of AD pathophysiology, and BMI in
both mid- and late-life cognitively normal individuals. We found that higher BMI was associated
with lower cortical Aβ burden in late-life participants. Although prior epidemiological work
suggests obesity increases the risk of AD228,229,234, the current finding showing a negative
relationship between BMI and Aβ burden is consistent with similar relationships found using
similar cohorts257,258.
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When examining BMI as a continuous variable we found that greater levels of BMI
were associated with lower levels of Aβ burden. This pattern was present in the late-life, but not
the mid-life cohort. Although some previous studies included individuals with mild cognitive
impairment and mild AD dementia, we found that this relationship persists even in a large cohort
that was limited to participants who were cognitively normal at baseline. This finding shows that
BMI and cortical amyloid burden can be directly related, and it gives a platform for future work
to elucidate whether the BMI-amyloid relationship is reflected by comorbid process or some
causal mechanism. If an aspect of body composition can become a biomarker for AD, then
identification of AD may be easier and expenditures may be minimized.
When examining BMI as a categorical variable (normal, overweight, and obese), we
found that there was a significant difference in the mean cortical Aβ burden between BMI groups
in late-life but not in mid-life. As seen with our analyses of BMI as a continuous variable, the
relationship was such that the categories representing greater levels of obesity on average had
less Aβ burden measured with PET. Prior work using a cognitively normal cohort or a mixed
cognitively normal and impaired cohort has found effects of continuous levels of BMI within
categories257,258. We found that when dividing the late-life group into three distinct BMI
categories (normal, overweight, and obese), the association between BMI and cortical Aβ burden
was non-significant in each of these three groups. Thus, our results show that the differences in
BMI within a restricted BMI range have less predictive power of cortical Aβ burden than the
BMI range an individual falls within. This is unsurprising as classifying individuals into BMI
groups constrains the range of BMI values, limiting the sensitivity as well as the interpretability
of such analyses.
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The results of this study support some of the findings from previous literature.
Specifically, higher BMI in late-life is associated with lower pathology258–262. However, our
study does not find evidence that higher BMI is associated with an increased risk of AD in midlife participants. As evidenced by our BMI x age-group model, the effect of BMI on cortical
amyloid burden differs by age group. One possible explanation for the non-significant finding in
the mid-life group, as opposed to the significant finding in the late-life group, is that the range of
Centiloid values is much narrower for the mid-life group. With greater longitudinal data it may
also be possible that mid-life obesity would later predict biomarkers in late-life.
We were also interested in whether the BMI-Aβ relationship is modified by the
presence of an APOE ɛ4 allele or by sex. APOE4 largely enhances Aβ pathology269,270 and is
associated with greater rates of cognitive decline271–274, so it is possible that being E4+ obscures
any relationship between BMI and Aβ. Alternatively, secondary health factors may only
exacerbate AD pathology in those with a predisposition toward elevated Aβ burden. There is also
a suggestion that Aβ accumulation in E4+ individuals is moderated by leptin signaling in the
hypothalamus and may in itself promote weight loss275, such that the inverse relationship
between BMI and Aβ may be stronger in E4+ individuals. However, we found no significant
BMI by APOE4 interactions in either mid-life or late-life, unlike a few previous studies257,275.
Additionally, we were interested in sex as a modifier of the BMI-Aβ relationship, as many
studies have found sex differences in AD276–278. We did not find any significant BMI by sex
interactions in either mid-life or late-life. Previous studies have shown differences in brain
atrophy rates277, cognitive decline276,277,279, mortality280, and CSF Aβ1 - 42278 but not Aβ
measured with PET277, so our finding is unsurprising.
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The inverse relationship of BMI-Aβ in late-life is counterintuitive to studies that have
shown BMI is associated with adverse health outcomes225,226. However, this “obesity paradox”
also appears in AD and dementia. In 40–45 year olds, obesity has been shown to increase the risk
of dementia later in life239. However, lower BMI in those aged over 65 is related to an increased
risk of dementia, AD, and vascular dementia228. Higher late-life BMI is also indicative of good
health status236, reduced risk of dementia237, and better cognitive performance238. The results of
our study support one component of the “obesity paradox” in AD. Specifically, that higher BMI
in late-life is associated with lower pathology, as other studies have shown258–262. However, our
study does not support the other component of the “obesity paradox” because we did not find
that higher BMI is associated with an increased risk of AD in mid-life participants. This
relationship should be explored in a larger sample of mid-life participants with longitudinal AD
pathology data to show the effects of an increasing BMI or sustained high BMI over time. This
may shed light on the relationship between a higher BMI and an increased risk of AD in mid-life
as reported by various studies239,281,282 and the possibility that the predictive ability of BMI
changes over time.
This study has several limitations. Firstly, BMI is a nonspecific measure of body
composition and may not accurately reflect the amount and distribution of body fat245,283,284.
Because the location of adipose tissue has been shown to be important in predicting dementia
risk284, a more specific measure of adiposity (e.g., waist circumference, percent body fat, and
skinfold thickness) may have better predictive ability of AD risk. In addition, there is a greater
misclassification inherent in BMI at mid-life in comparison to late-life229. The variation of
adiposity in an individual throughout life stages warrants a more accurate measurement of
adiposity that can be used in future studies relating BMI and AD pathology.
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Our study did not assess the relationship between BMI and Aβ over time. As obesity
represents a chronic condition, it may be necessary to examine the relationship between obesity
and AD pathology over the course of decades. Such analyses would also be able to take into
account common weight declines that occur before clinical AD onset285. Additionally, a
longitudinal analysis could shed light on the association between BMI and rate of Aβ
accumulation. We would also be able to assess if mid-life obesity predicts AD or dementia in
late-life, as indicated by other studies239,281,282. The limitations of our data indicate that our
results should not be interpreted as evidence for a temporal or causal relationship between BMI
and Aβ.
It is also possible that BMI is related to other biomarkers (e.g., CSF Aβ, total tau, p-tau,
tau PET, [18F]-fluorodeoxyglucose PET, and structural MR). It would be worthwhile to see if
lower late-life BMI is associated not only with an elevated Aβ burden but also a greater rate of
tau accumulation or neurodegeneration after AD onset. Future studies should investigate the
relationship between BMI and these other biomarkers in an effort to isolate the associations
between BMI, AD risk, and pathology after AD onset. Finally, any group of individuals who
agree to participate in longitudinal studies in which molecular biomarkers of AD are obtained are
not representative of the population from which they are recruited, so our results may not be
generalizable.
Our study also had a number of strengths. Our sample of CN adults at baseline was
large, especially for the late-life group. The primary models accounted for multiple demographic
variables and the primary genetic risk factor for sporadic AD—APOE genotype. Additionally,
we were able to investigate the relationship of continuous BMI and cortical Aβ in BMI and
APOE4 subdivisions. Furthermore, we were able to directly relate a high Aβ burden, a marker of
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increased dementia risk, directly with BMI in cognitively normal elderly. Future studies will be
able to use this baseline data and harmonize with other databases that have been successfully
enrolling cognitively normal participants at baseline and tracking multiple AD biomarkers in
these same participants over time.
Ultimately, exploring the relationship between BMI and AD biomarkers is important to
better quantify risk of progressing to symptomatic stages of AD. The results from our study
reinforce the need to monitor unintentional weight loss closely in older adults. Future studies
should investigate the longitudinal association between adiposity and Aβ and examine whether
the association between BMI and AD is mediated by possible confounding factors, like
cardiovascular health, diabetes, and other disease conditions.
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Chapter 4: Exploring Strategies for
Individual Patient Trajectory Modeling
4.1 Modeling Autosomal Dominant Alzheimer’s Disease
with Machine Learning (Luckett, McCullough et al., 2021)

Section 2.2 was taken from previously published co-author work286. I was heavily involved in
data gathering, experimental design and methodology development, and manuscript design and
revision, along with providing guidance and feedback throughout the processing,
experimentation, and testing phases. I was not primarily responsible for the specific
programming, training, and validation of the models.

4.1.1 Introduction

Alzheimer's disease (AD) is the most common form of dementia, accounting for 60% to 70% of
the 50 million dementia cases worldwide287. AD leads to slow cognitive decline, behavioral and
psychiatric disorders, and impairments in functional status. Pathological features of AD include
the accumulation of amyloid beta (Aβ) plaques, neurofibrillary tau tangles, and
neuronal/synaptic losses that correspond with atrophy and decreased glucose metabolism288. The
most common form of AD occurs in older age and is known as late-onset Alzheimer's disease
(LOAD). Autosomal dominant Alzheimer's disease (ADAD) accounts for <1% of all AD cases
and is caused by pathogenic mutations in amyloid precursor protein (APP), presenilin 1
(PSEN1), or presenilin 2 (PSEN2) genes that lead to early increases in Aβ deposition in the
brain, which, in turn, is hypothesized to initiate a cascade that causes cognitive decline289,290. The
age of onset of cognitive impairment in ADAD mutation carriers (MC) is earlier than LOAD and
remains fairly consistent within a family, allowing for calculation of the estimated age of
symptom onset (EAO)291.
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Multiple neuroimaging methods have been used to evaluate in vivo changes in the brain
due to AD. [11C] Pittsburgh compound B (PiB) has high affinity for Aβ plaques, with
distributions similar to those seen at autopsy292. PiB positron emission tomography (PET) has
been used in ADAD to identify amyloid deposition, with amyloid deposition identified >20 years
prior to EAO in MC293–296.
Studies have also shown increases in PiB retention in MC are associated with a
worsening cognitive performance, a decrease in glucose metabolism, and a decrease in
hippocampal volume293,297.
[18F] Fluorodeoxyglucose (FDG) uptake reflects glucose metabolism and has shown
promise in discriminating symptomatic MCs from cognitively normal, mutation-negative noncarriers (NC)292,295,296. In ADAD, studies have shown FDG uptake in MCs is decreased in the
precuneus and is inversely correlated with PiB binding. Marked decreases in glucose metabolism
occur approximately 5 to 10 years before EAO in MCs296,298.
Structural magnetic resonance imaging (MRI) provides a method to evaluate regional
volumetric changes in neurodegeneration that occur with disease progression299. MRI can reveal
regional brain atrophy, which is a characteristic feature of neurodegeneration due to synaptic
losses300. ADAD is characterized by progressive atrophy that manifests as changes initially in the
temporal lobes and subcortical regions with eventual spread to other regions. Observed changes
in atrophy are related to the spread of neurofibrillary tangles in AD300.
Machine learning (ML) is a branch of artificial intelligence that can learn to extract
patterns from existing data to predict future events301. Advances in ML offer promise for a
number of applications, including medical imaging and predictive analytics301,302. Compared to
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traditional statistics that provide primarily group-level results, ML algorithms can predict clinical
outcomes at the individual level and could enable personalized treatments that provide targeted
care for patients303. Although a number of studies have applied ML to neuroimaging measures to
study LOAD304–308, few studies to date have applied these techniques to ADAD. Because time
until conversion to symptomatic impairment can be estimated with EAO, ADAD provides a
unique opportunity for ML to model the progression of the disease and provide decision support
to evaluate therapies currently being investigated in the Dominantly Inherited Alzheimer
Network Trials Unit (DIAN-TU).
In this longitudinal study, we used artificial neural networks (ANNs) to evaluate
progression to cognitive impairment using multimodal neuroimaging biomarkers. Specifically,
within a cohort of MCs (n = 131) and NCs (n = 74), we used ANNs to investigate: (1) changes in
Aβ deposition (using PiB), (2) changes in glucose metabolism (using FDG), and (3) brain
atrophy (using structural MRI) as a function of aging in relation to EAO. Further, we used
feature selection to identify regions that were the strongest discriminators of mutation status for
each modality. We then performed Monte Carlo simulations to identify cutoffs for the identified
regions. This data-driven approach provides an opportunity to discover novel mechanisms and
disease trajectories specific for ADAD.

4.1.2 Methods
Participants

One hundred thirty-one MCs with mutations in PSEN1, PSEN2, or APP and 74 healthy,
mutation-negative NCs were recruited from sites participating in the DIAN study. Participants
from the 12th data freeze with genetic, clinical, and longitudinal neuroimaging data that passed
quality control procedures were included. The Washington University Institutional Review
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Board provided supervisory review and human subjects’ approval. Participants provided written,
informed consent, or assent with proxy consent. All study procedures were approved by the
Washington University Human Research Protection Office and the institutional review boards of
the participating sites.
Clinical classification
The Clinical Dementia Rating (CDR®) Dementia Staging Instrument was used to assess
dementia status at each clinical assessment309. A participant's EAO was calculated at each visit
on the basis of the participant's current age relative to the family mutation–specific expected age
at onset of dementia symptoms291. Parental age at first progressive cognitive decline was used if
the mutation-specific EAO was unknown. EAO was calculated identically for both MCs and
NCs. All clinical evaluators were blinded to the mutation status of participants. The
presence/absence and type of mutation were determined using polymerase chain reaction
amplification followed by Sanger sequencing293.
MRI acquisition and processing
MRI was performed using the Alzheimer's Disease Neuroimaging Initiative (ADNI) protocol310.
Sites used a 3T scanner that passed regular quality control assessments. The ADNI Imaging Core
screened images for compliance. T1 weighted images at 1.1 × 1.1 × 1.2 mm voxel resolution
were acquired for participants. FreeSurfer 5.3311,312 was used to perform volumetric
segmentation, cortical surface reconstruction, and to define cortical and subcortical regions of
interest (ROIs). Segmentations were inspected and edited as needed by members of the DIAN
Imaging Core. A regression approach was used to correct subcortical volumes for intracranial
volumes. Volumetric measures were averaged across hemispheres. FreeSurfer-defined cortical
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and subcortical ROIs (44 total) were used for regional processing of PET data. The FreeSurferdefined ROIs were derived from the Desikan/Killiany atlas313 for segmentation. These are
standard regions used for volumetric analyses.
PET acquisition and processing
Amyloid PET was performed using a bolus injection of PiB. Data from 40 to 70 minutes postinjection were converted to regional standardized uptake value ratios (SUVRs) relative to the
cerebellar gray matter using FreeSurfer-derived ROIs (PET Unified Pipeline)314. Glucose
metabolism imaging was performed with a single bolus injection of FDG. A 30-minute dynamic
acquisition beginning 30 minutes post-injection was acquired. The last 20 minutes of each FDG
scan were converted to SUVRs using the cerebellar gray matter as a reference region. All PET
data were partial volume corrected using a regional spread function technique150,315. PET images
were aligned to the T1 image processed using FreeSurfer. PET scanner–specific filters were
applied to account for differences in spatial resolution and to achieve a common resolution (8
mm)316. The DIAN imaging core performed quality control checks on the PET Unified Pipeline
processing.
Machine learning and statistical analyses
ML analyses were performed in MATLAB R2018b. Deep feedforward ANNs were trained for
each of the neuroimaging modalities. Feedforward ANNs map an input to an output by
composing sets of smaller functions laid out as a directed acyclic graph317. The feasibility of
these networks is based on the universal approximation theorem, which states a neural network
with a single hidden layer contains a finite set of artificial neurons that approximate continuous
functions on subsets of Rn318.
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Our ANNs contained four hidden layers with 10 artificial neurons in each layer. The
network architecture was decided based on design methodologies319,320, incremental pruning, and
cross-validation. Further details on model design and validation can be found in supporting
information (Methods—Machine Learning Model Design). An ANN was trained to output all
ROIs for each modality. Input to the models included age, sex, apolipoprotein E (APOE) ε4
status, mutation status, the amount of time in the future to predict, and the given imaging
variables (MRI or SUVR) for 44 FreeSurfer ROIs. A complete list of the ROIs can be found in
Table S1 in supporting information. The output of each model corresponded to the ROI values at
a time point in the future. Rates of change were calculated by subtracting scans at time point N
by the scan at time point N–1. Rates were then divided by the number of months between the
scans to obtain a normalized rate of change. The mean time between scans was 2.6 years (±1.4).
If a participant had more than two scanning sessions, all possible combinations were evaluated.
Using the first time point, data were projected into the future by iteratively adding the
normalized rate of change, and these data were used for training. For each point, the rate of
change was used to project the data ±3 years from the current age. Data were projected into the
future and the past to avoid biasing the model to later phases of the disease. We chose this
window based on previous work296, which showed the biomarkers’ rate of change is not constant
along the disease continuum.
Predictive features of mutation status were ranked according to importance using a Relief
algorithm321. Relief algorithms detect conditional dependencies between attributes using a
nearest neighbor approach, with features ranked by estimating how well their values distinguish
between proximal comparisons. Further, cutoff points for PiB, FDG, and brain volumetrics were
identified based on the likelihood of the values generated by Monte Carlo model simulations.
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The simulations generated an equal number (by mutation status) of random sample points from
the multivariate distribution defined by the mean and covariance matrix of the data given a
specific mutation status, age, and EAO range322.
We also trained a linear regression model to compare the results to our ANN. This
comparative analysis was performed due to recent research suggesting that, in some cases, linear
models can outperform nonlinear models323. When training the regression model, all methods
previously described for training the ANN were applied. Each biomarker was modeled
separately, and the models were trained using five-fold cross-validation. Cross-validation was
performed at the participant level, and all results reported were derived by combining the test
data results from each of the five folds of cross-validation. In addition, the input to the regression
model was the same as the ANN, but the only output considered was the precuneus. We chose
the precuneus as it is highly predictive and heavily involved in disease progression in ADAD296,
making it optimal for comparison. Further, a multivariate linear regression was performed that
derived brain regions in the same manner as the ANN. The regression model used ordinary
multivariate normal maximum likelihood estimation with the full variance-covariance matrix and
constant, linear, and interaction terms. We also performed the zero-rule algorithm on the data to
compare baseline predictability using the mean of the output values observed in the training data
compared to the testing data.

4.1.3 Results

Demographics of the cohort
Detailed demographics are presented in Table 4.1. Participants were matched for age, sex, and
education.
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Table 4.1. Demographics of participants.
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PiB
The Relief algorithm identified the nucleus accumbens, caudate, precuneus, anterior cingulate,
pallidum, putamen, and middle frontal regions as strong predictors of mutation status. The ANN
was able to predict the future PiB values with an average R2 value of 0.95 and root mean square
error (RMSE) of 0.2. Figure 4.1 depicts results for the four best-predicted ROIs. The algorithm
was able to accurately estimate the values in both MCs and NCs, with the NCs having lower
SUVRs compared to the MCs. Supp. figure 4.1 in supporting information shows the model
predictions for MCs based on distance from EAO for PiB. Two relatively distinct clouds were
seen for PiB, with lower SUVRs seen at greater distances from EAO, while MCs closer to EAO
had elevated PiB SUVRs.
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Figure 4.1. Results of Pittsburgh compound B (PiB) predictions for mutation carriers (MC; blue) and non-carriers
(NC; red). Correlation and root mean squared error (RMSE) of predicted versus actual values. The artificial neural
network (ANN) was able to predict future PiB values with an average R2 of 0.95 and RMSE of 0.2 in both MCs and
NCs. SUVR, standardized uptake value ratio
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FDG
The strongest predictors of mutation status with respect to metabolism were the pericalcarine,
caudate, precuneus, fusiform, anterior cingulate, insula, and transverse temporal regions. The
ANN was able to predict future FDG values with an R2 value of 0.93 and RMSE of 0.02 in both
groups. Figure 4.2 depicts results for the four best-predicted ROIs. The algorithm showed a trend
of MCs having lower future FDG values than NCs. Supp. figure 4.2 in supporting information
shows the model predictions for MCs based on distance from EAO for FDG. Two clouds are
seen for FDG, with higher SUVRs seen at greater distances from EAO, while MCs closer to
EAO had lower FDG SUVRs.
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Figure 4.2. Results of fluorodeoxyglucose (FDG) predictions for mutation carriers (MC; blue) and non-carriers (NC;
red) in select regions of interest. Correlation and root mean squared error (RMSE) of predicted versus actual values.
The ANN was able to predict future FDG values with an average R2 of 0.93 and RMSE of 0.02 in MCs and NCs,
with MCs showing trends of lower predicted FDG values than NCs. SUVR, standardized uptake value ratio
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Volume
The strongest predictors of mutation status with respect to brain atrophy were seen in the nucleus
accumbens, pericalcarine, caudate, precuneus, anterior cingulate, insula, entorhinal cortex,
pallidum, and transverse temporal regions. The ANN was able to predict changes in brain
volumes with an average R2 value of 0.95. Figure 4.3 depicts results for the four best-predicted
regions. The algorithm showed a general trend of MCs having more brain atrophy than NCs.
Supp. figure 4.3 in supporting information shows the model predictions for MCs as a function of
distance from EAO for brain volumes.
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Figure 4.3. Results of brain volumetric predictions for mutation carriers (MC; blue) and non-carriers (NC; red).
Correlation and root mean squared error (RMSE) of predicted versus actual values. The artificial neural network
(ANN) was able to predict changes in brain volumes with an average R2 value of 0.95 and showed a general trend
of MCs having more brain atrophy than NCs
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Simulations
Using the trained models, amyloid accumulation, changes in metabolism, and brain atrophy were
simulated for MCs and NCs (Figure 4.4, top). Consistent with previous work, the models showed
that in the MC group, the earliest changes are in amyloid deposition, which follows a sigmoidal
trajectory and continues to accumulate past EAO. A biphasic response was seen for metabolism,
with changes occurring earlier than expected, and progressive decline was observed in atrophy
throughout the course of the disease, with the greatest changes occurring just prior to EAO. The
NC groups showed little change over time for all modalities.
Figure 4.4 (bottom right) shows the normalized model errors based on years to predict
(eg, the error for a participant's PET/MRI values predicted 1 year in the future vs the error for
predicting 5 years in the future). A two-degree polynomial curve was fit to the error data, which
showed a predominantly linear increase with increasing number of years to predict. The fit lines
were projected into the future for up to 40 years. The plot shows that the model maintains a mean
absolute error <0.1 up to 10 years in the future. The individual biomarkers showed similar trends,
only at different scales.
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Figure 4.4. Top left, Simulated biomarker evolution for total mean cortical and subcortical Pittsburgh compound B
(PiB), total mean cortical and subcortical fluorodeoxyglucose (FDG), and total gray matter volume (scaled to a
common interval) derived from the artificial neural network (ANN) in mutation carriers (MC). Shaded region
indicates model variability, with estimated age of onset (EAO) marked by perpendicular line. Top right, Simulated
biomarker evolution for total mean cortical and subcortical PiB, total mean cortical and subcortical FDG, and total
gray matter volume (scaled to a common interval) derived from the ANN in mutation non-carriers (NC). Bottom
left, Normalized biomarker rate of change for mean PiB, mean FDG, and total gray matter volume (scaled to a
common interval) fit to a polynomial curve showing 95% confidence interval. Bottom right, Mean absolute error of
predicted (normalized) biomarker values given the amount of time in the future to predict, fit with a two-degree
polynomial curve projected into the future. Errors increased linearly with an increase in the amount of time in the
future to predict. SUVR, standardized uptake value ratio
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Supp. figures 4.4–4.6 in supporting information display the results of the Monte Carlo model
simulations for each of the highly predictive regions for each modality. Larger values on the yaxis represent a greater likelihood of producing a given value. For PiB, clear cut-points were
observed between MCs and NCs with nearly 100% specificity. Cut-points were 1.17 for the
nucleus accumbens, 1.3 for the caudate, 1.4 for the precuneus, and 1.2 SUVR for total cortical
mean. For FDG, the cut-points were less defined for some regions. Cut-points for the anterior
cingulate, caudate, precuneus, and total cortical mean ranged from 1.4 to 1.825 SUVR. The
model simulations indicate MCs had a trend for decreased FDG in each of these ROIs, as well as
a biphasic response in the caudate and anterior cingulate. For brain volumes, MCs had greater
atrophy than NCs. Cutoffs were identified for the nucleus accumbens (550 mm3), caudate (3300
mm3), precuneus (8500 mm3), and total gray matter (575,000 mm3).
Alternative analysis methods
Supp figure 4.8 in supporting information displays the error histograms (probabilities of errors
[actual–predicted]) for the ANN versus the regression model for PiB in the precuneus. Although
both models performed very well, the performance obtained through regression was lower than
that obtained through the ANN. The ANN's error probability distribution was highly clustered
around 0 (RMSE = 0.17), whereas the regression model showed greater dispersion (RMSE =
0.28), indicating a greater likelihood of making a larger error compared to the ANN. Similar
results were seen using FDG and volumetric data. Whole brain average RMSE for the ANN,
multivariate linear regression, and zero-rule algorithm are provided at the bottom of Supp. table
4.1. As expected, the ANN showed lower RMSE compared to multivariate linear regression and
the zero-rule algorithm for all modalities.
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4.1.4 Discussion

Our models yielded high accuracy in predicting amyloid accumulation, changes in metabolism,
and brain atrophy in ADAD. The Relief algorithm identified both subcortical (caudate) and
cortical (precuneus and anterior cingulate) ROIs as the strongest predictors of mutation status.
Figure 4.5 displays the strongest predictors for each modality. For amyloid PET, which is
believed to reflect the earliest changes in ADAD, changes were primarily seen within subcortical
(pallidum, nucleus accumbens, caudate, putamen, and entorhinal) compared to cortical regions
(middle frontal, anterior cingulate, and precuneus). For changes in metabolism measured by
FDG, which reflect changes later in the disease process compared to amyloid, more cortical
(insula, fusiform, middle frontal, precuneus, anterior cingulate, pericalcarine, and transverse
temporal) rather than subcortical (caudate) regions were involved.

Figure 4.5. Strongest predictors of mutation carrier (MC) status for autosomal dominant Alzheimer's disease
(ADAD) as identified by Relief algorithms. The strongest predictors across all modalities were the precuneus,
caudate, and anterior cingulate. Changes in amyloid positron emission tomography (Pittsburgh compound B [PiB],
blue circle) were primarily seen within subcortical regions. Changes in metabolism (fluorodeoxyglucose [FDG],
orange circle) showed more cortical involvement. Volumetric changes (Volume, green circle) showed both cortical
and subcortical involvement
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For changes that occur late in the disease process due to atrophy, both cortical
(precuneus, anterior cingulate, pericalcarine, transverse temporal) and subcortical (caudate,
pallidum, nucleus accumbens, entorhinal, thalamus) regions were affected. This suggests that the
disease may start within subcortical areas and quickly involve additional subcortical and cortical
regions. Overall, these analyses point to multiple hubs being affected early in the disease
process, followed by spread to other brain regions (Supp. figure 4.7 in supporting information).
Supp. table 4.1 lists the RMSE for the individual ROIs for each of the three biomarkers, as well
as the mean overall RMSE of the models compared to the zero-rule algorithm and multivariate
linear regression.
In the amyloid analysis, the model achieved 0.95 R2 and 0.2 RMSE (see Figure 4.1). The
model showed PiB uptake was greater in MCs compared to NCs for most regions. Our results
also confirm that the presence of amyloid alone is insufficient for conversion to symptomatic
AD. The simulated trajectory for mean cortical amyloid accumulation (see Figure 4.4, top left)
showed deposition started to occur approximately 15 to 20 years before EAO. These results are
consistent with other studies that focused on global and regional amyloid deposition293,297. Our
model indicates a sigmoidal trajectory of accumulation for amyloid, with a slow increase 20 to
30 years from EAO, an abrupt increase 0 to 15 years from EAO, and slowing to an eventual
decline after EAO. This is consistent with what has been hypothesized to occur in LOAD324.
As a point of reference, we calculated the normalized rates of change for all mutationpositive participants (see Figure 4.4, bottom left). The normalized rate of amyloid deposition
shows a consistent increase from roughly 10 years prior to EAO followed by slowing in the rate
of accumulation after EAO. Only after EAO does the rate of accumulation diminish, which is
consistent with the sigmoidal model trajectory.
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With regard to metabolism, our model yielded 0.93 R2 and 0.02 RMSE. Although the
MCs had greater decrease in FDG for most brain regions, the separation between the two groups
was not as well defined compared to PiB. This is likely because the rate and amount of change
are less extreme compared to amyloid (see Figure 4.4, top left). Our model indicates metabolism
did not decrease below a baseline until 10 years before symptom onset and continued to decline
after EAO. These results are consistent with the normalized rate of change (see Figure 4.4,
bottom left). The rate of metabolism did not decline below baseline until 10 years prior to EAO,
followed by a steady decline.
An uptick in metabolic activity was observed in the early stages of amyloid accumulation
and did not begin to decrease until amyloid significantly increased. This was observed in the
simulated trajectory and the normalized rate of change. Similar results were observed within the
precuneus in a cross-sectional analysis293. Rate of change analysis revealed this primarily occurs
in the basal ganglia. Because the basal ganglia show the least toxic response to amyloid
deposition325–327, these transient increases may be prominent because these neurons mount a
compensatory response preceding significant amyloid accumulation328–332. However, at some
point, the brain is no longer able to buffer changes when amyloid deposition becomes significant.
Our model showed total gray matter volume slightly declined during the early stages of
ADAD, followed by a dramatic decrease 5 to 10 years prior to EAO. The decrease in volume
occurred when metabolism was decreased and amyloid had accumulated. Volumetrics continued
to decline even after EAO. The model was able to predict volumes with an R2 of 0.95.
These findings have clinical importance for the care of people with ADAD in the context
of amyloid, metabolism, and atrophy. Using feature selection methods, we have identified brain
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regions that are both common among modalities as well as unique for each modality (Figure
4.5). Specifically, we have shown the precuneus, caudate, and anterior cingulate are strong
predictors of mutation status among all modalities. These findings are significant for multimodal
imaging studies and clinical trials whose goal is to assess the overall impact of a therapy.
Further, the fact that we have identified regions that are unique to each modality suggests a
complex set of evolving interactions that are not localized to a small set of brain regions. Our
models also suggest a complex disease progression that goes beyond a linear or sigmoidal pattern
that has been hypothesized for LOAD (Figure 4.4). We have identified a biphasic response in
metabolism, in which hypermetabolism is seen very early in the disease process. Future studies
should investigate this phenomenon, as previous studies have primarily focused on
hypometabolism that occurs later in the disease process.
We also extend the literature by establishing clinically useful algorithms for modeling the
progression of ADAD, and show the utility of ML in developing diagnostic and predictive tests.
A major deficiency in AD clinical research is the problem of individual predictability versus
group-level differences. ML is ideal for research aimed at discovering patterns in highdimensional data that are believed to underlie complex clinical phenotypes that go beyond
group-level results. This is especially relevant for diseases such as ADAD and LOAD, which
show chronic progression over long periods of time, as well as variability in terms of symptoms,
risk factors, and progression. Our models were trained on the largest available ADAD data set
and are able to accurately forecast disease progression several years into the future at any stage
of the disease. Inputting a patient's unique demographics and imaging variables will yield
trajectories that are specific to that individual. Further, by simulating our trained models, we are
able to identify trajectories and cutoff values unique to each brain region that best discriminate
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MCs from NCs. Because our models have been trained on a variety of demographics, one can
easily generate values that are specific to a given sex, APOE ε4 status, and education level. Use
of these models provides the opportunity to expedite clinical trials and provide precision
medicine tailored to a patient based on his/her unique set of demographics, disease subtype, and
treatment response. As we have shown, while both linear regression and our ANN performed
well in predicting disease progression, the ANN had a lower error rate. More accurate models
could lead to better decision making and improved efficiency of research, and accurate
identification of participants whose progression patterns differ from model predictions could
allow for decision support in evaluating the effects of specific therapies in clinical trials.
Limitations and future work for this study are detailed as follows. Data leakage, which
refers to the use of test data in any part of the training process, is a major concern in the AD
field333, and is difficult to address due to the limited number of samples. This is especially
relevant in the context of ADAD. While we use the largest available data set, the fact that ADAD
only accounts for a small portion of the total AD cases restricts the number of available of
samples. Still, choosing the proper set of hyperparameters in the context of deep neural networks
is a difficult task. However, the performance and flexibility of these models crucially depends on
how these parameters are set334. In our analysis, the number of layers and number of artificial
neurons in each layer were identified by testing multiple network architectures within our data
(see supporting information). Measures were taken to ensure that the partitioning of the data for
five-fold cross-validation in this process did not match the data partitions used for the five-fold
cross-validation for the final analysis. We also ensured the models trained in the network
architecture identification process were discarded after the fact, and all subsequent models
generated in the main analysis had randomly initialized weights. However, because the same
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data set was used to identify the size of the network as well to perform the main analysis, we
acknowledge that this could be a source of data leakage, which could lead to an underestimation
of errors. Future work will involve further validation and testing of the proposed models.
Specifically, conducting blinded out-of-sample testing on newly acquired data from the DIAN
study is needed to ensure issues such as data leakage and overfitting do not influence the model
results. Further, alternative network models will need to be considered. As more longitudinal
time points are acquired for participants in DIAN, time series–specific networks, such as long
short-term memory network may be more appropriate. Last, alternative forms of feature selection
should be considered to investigate the relationships between biomarkers and brain regions.

4.1.5 Conclusion

To provide targeted treatment to persons with ADAD, novel methods are needed to model
disease trajectories. We have shown ANNs can accurately forecast amyloid accumulation,
changes in glucose metabolism, and brain atrophy. Using feature extraction methods, we
identified the strongest predictors of mutation status over 44 brain regions. Our results show a
sigmoidal progression of amyloid accumulation, a biphasic response to glucose metabolism, and
a gradual increase in brain atrophy in MCs compared to NCs. Our models indicate disease
progression is primarily in subcortical regions, followed by cortical involvement within anterior
and posterior portions of the brain.
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4.1.7 Supplemental Information
Machine Learning Model Design

Given the prediction problem we aimed to solve, as well as the structure and characteristics of
our data set, the appropriate and standard neural network architecture was the multilayer
perceptron. In the initial pruning stage, multiple network architectures were trained and
compared, with the smallest network containing a single hidden layer and 5 artificial neurons,
and the largest network containing 5 hidden layers with 20 artificial neurons in each layer. An
architecture was considered acceptable if the R2 value was at least 0.9 for all 5 folds of crossvalidation. An architecture was considered unacceptable if the R2 value was less than 0.9, or if a
smaller architecture could achieve the same or better results. This process was performed for the
three biomarkers separately, and the smallest architecture that satisfied the criteria for all three
biomarkers was selected (4 hidden layers, each with 10 artificial neurons).
Within every artificial neuron, a hyperbolic tangent transfer function was used for
activations. Hyperbolic tangent transfer functions are generally preferred over other transfer
functions in hidden layers because they produce outputs that are centered near zero, which makes
training more efficient due to the normalization effect of the function’s output. Because our
targets were multiple continuous variables, a linear transfer function was used in the output layer.
The models were trained using Levenberg-Marquardt backpropagation with a root mean squared
error (RMSE) cost function335.
The ANNs were trained using nested 5 fold cross-validation to prevent overfitting and
leakage336. For each fold of cross-validation, the data were partitioned into training (80%) and
testing (20%) sets. Because some participants had numerous scan sessions, the partitioning was
performed at the “participant level” instead of at the “scan session level.”
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This ensured that a participant’s data were used for testing in only one of the 5 folds and that no
participant could be in both training and testing data in any of the folds. Further, the 80%
training data within each of the 5 folds were randomly partitioned into training (70%) and
validation (30%) sets. Training was terminated at either 100 iterations or 10 successive
validations without improvement. All results reported were derived by combining the test data
results from each of the 5 folds of cross-validation.
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Supplementary Figures

Supp. Figure 4.1. Pittsburgh Compound-B (PiB) model predictions for mutation carrier participants based on
expected years to symptom onset (EYO) in the precuneus.
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Supp. Figure 4.2. Fluorodeoxyglucose (FDG) model predictions for mutation carrier participants based on distance
from expected age of symptom onset (EAO) in the precuneus.
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Supp. Figure 4.3. Volume model predictions for mutation carrier participants based on distance from estimated
years to symptom onset (EYO) in the precuneus.
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Supp. Figure 4.4 Results of Monte Carlo PiB simulations. X-axis represents PiB value, y-axis represents likelihood
of model producing the given value.
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Supp. Figure 4.5. Results of Monte Carlo FDG simulations. X-axis represents FDG value, y-axis represents
likelihood of model producing the given value.
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Supp. Figure 4.6. Results of Monte Carlo volume simulations. X-axis represents volume, y-axis represents
likelihood of model producing the given value.
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Supp. Figure 4.7. Regions most affected by autosomal dominant Alzheimer’s disease (ADAD) based on feature
selection and Monte Carlo simulations. Regions identified were primarily in subcortical, middle frontal, and
posterior parietal regions.
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Supp. Figure 4.8. Error probability for deep net (ANN) and regression model. While both models perform well, the
deep net’s error distribution shows that it outperforms typical regression models.
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Supp. Table 4.1. Root mean squared error by ROI for biomarkers

PiB

FDG

Volume (Scaled by ROI
magnitude)

Accumbens

0.144

0.023

0.798

Amygdala

0.121

0.013

1.232

Brain stem

0.12

0.011

8.73

Caudal anterior cingulate

0.154

0.02

2.519

Caudate

0.146

0.02

1.818

Choroid plexus

0.147

0.014

1.858

Cortical mean/total gray

0.135

0.018

103.5

Cuneus

0.149

0.038

2.211

Entorhinal

0.139

0.017

2.029

Frontal pole

0.229

0.053

0.876

Fusiform

0.126

0.016

6.331

Hippocampus

0.21

0.022

4.84

Inferior parietal

0.142

0.025

6.834

Inferior temporal

0.125

0.017

7.274

Insula

0.128

0.014

3.325

Isthmus cingulate

0.139

0.027

1.898

Lateral occipital

0.134

0.036

6.529

Lateral orbitofrontal

0.135

0.019

2.772

Lingual

0.129

0.022

3.17

Medial orbitofrontal

0.157

0.021

3.409

Middle temporal

0.122

0.02

6.022

Pallidum

0.147

0.02

1.692
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Paracentral

0.144

0.023

2.339

Parahippocampal

0.159

0.014

1.501

Pars opercularis

0.133

0.022

2.916

Pars orbitalis

0.159

0.032

1.456

Pars triangularis

0.142

0.028

2.649

Pericalcarine

0.254

0.026

1.501

Posterior cingulate

0.144

0.02

2.34

Postcentral

0.175

0.022

4.909

Precentral

0.121

0.021

6.251

Precuneus

0.168

0.03

3.972

Putamen

0.162

0.015

3.849

Rostral anterior cingulate

0.159

0.022

2.239

Rostral middle frontal

0.153

0.029

8.227

SST banks

0.175

0.025

2.137

Superior frontal

0.138

0.02

8.742

Superior parietal

0.146

0.029

6.419

Superior temporal

0.12

0.02

5.449

Supramarginal

0.13

0.022

6.017

Thalamus

0.122

0.013

5.532

Temporal pole

0.123

0.02

2.051

Transverse temporal

0.178

0.036

0.944

Ventral diencephalon

0.12

0.012

1.688

ANN Mean RMSE

0.15

0.02

5.97
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Baseline (ZeroR) Mean RMSE

1.26

.48

39.34

Multivariate Linear Regression Mean
RMSE

0.23

0.11

9.73
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Chapter 5: Understanding How State-of-theArt Disease Modifying Therapies Interact
with Patient Pathology Trajectories
5.1 Regional Effects of Gantenerumab on Neuroimaging
Biomarkers in the Dominantly Inherited Alzheimer Network
Trials Unit 001 (McCullough, Chen, & Gordon et al., in
prep.)
Section 5.1 was taken from first author work that is in preparation for journal submission.

Importance: There is an urgent need to understand what impact anti-amyloid treatment
with gantenerumab has on amyloid-β plaques, glucose metabolism, and cortical atrophy in
distinct regions of the brain to inform future drug trial and treatment plan design in the autosomal
dominant Alzheimer disease population. Objective: To assess how regional analysis of DIANTU-001 trial results informs overall conclusions about the successful reduction of global amyloid
plaque levels with prolonged gantenerumab treatment. Design, Setting, and Participants: The
DIAN-TU-001 trial randomized 144 DIAD mutation carriers to receive continuous quad-weekly
subcutaneous injections of either 225 mg gantenerumab, 400 mg solanezumab, or placebo. A
dose escalation protocol was instituted midway through the study with target doses of 1200 mg
gantenerumab and 1600 mg solanezumab. Biomarkers were assessed at baseline and years 1, 2,
and 4. Participants were known to have a DIAD mutation, be between 15 to 10 years after their
expected age of symptom onset, and a CDR of 0 (cognitively normal) or 0.5-1 (early dementia).
DIAD mutation carriers were randomized 3:1 to active or placebo with a minimization
procedure. Main Outcomes and Measures: The primary outcomes were the longitudinal effects
of gantenerumab treatment on regional PiB PET, FDG PET, and MRI neuroimaging variables.
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Results: Treatment with Gantenerumab significantly reduced the longitudinal increase of mean
cortical PiB PET signal relative to the placebo group. Additionally, Gantenerumab treatment
significantly reduced longitudinal PiB PET in 32 cortical and 6 subcortical regions. The strength
of the drug effect on longitudinal PiB PET values varied considerably with the most significant
drug effects seen in the dorsal striatum, thalamus, nucleus accumbens, caudal anterior cingulate,
rostral anterior cingulate, and medial orbitofrontal regions. Posterior cortical structures with
prominent baseline PiB PET signal showed noticeably smaller, but still significant drug effects
(precuneus, posterior cingulate, isthmus cingulate). Regional PiB reduction levels were
significantly correlated with regional baseline PiB PET values, but only minimally correlated
with mean regional blood flow data from an age and sex matched cohort. No statistically
significant drug effects were found in the regional analyses for FDG or MRI. Conclusions and
Relevance: Treatment with gantenerumab significantly reduced global PiB PET signal in DIAD
participants over a four-year trial period. The estimated drug effect was not uniform across the
brain but varied regionally, with the highest levels of signal reduction in the basal ganglia and
medial frontal structures. Regional variations in PiB results were correlated but not solely
explained by levels of baseline Aβ pathology present in each region.

5.1.1 Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a decades long
cascade of pathological changes preceding the onset of clinical dementia. It is hypothesized that
the formation of extracellular amyloid beta (Aβ) plaques is critical in initializing destructive
cellular processes that culminate in widespread neuronal dysfunction and death and the buildup
of neurofibrillary tangles (NFTs) primarily composed of hyperphosphorylated tau protein337,338.
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It affects an estimated 6.2 million individuals aged 65 or older in the United States alone, with an
estimated national healthcare cost burden of $355 billion339.
Clinical trials have focused primarily on anti-Aβ therapies, given its prominent early role
in the disease340–343. The primary methods used to lower Aβ have been either altering β-site
amyloid precursor protein cleavage (BACE inhibitors344–349), or monoclonal antibody therapies
that recognize soluble (e.g. solanezumab350,351) or aggregated forms of Aβ (e.g. gantenerumab352–
356

). Despite these promising approaches, these trials have mostly failed to meet their originally

stated endpoints. Reasons for these past results could include targeting individuals too late in the
disease course, inadequate or poorly optimized dosing, poor target engagement, and the
influence of comorbidities contributing to dementia in trial populations357–360.
Dominantly inherited Alzheimer’s disease (DIAD) is a rare form of the disorder caused
by mutations in the presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein
(APP) genes. In DIAD, dementia onset occurs at an early age that is relatively free of comorbid
pathology and onset age is inheritable and highly predictable361,362. These unique properties
make DIAD a powerful model to study the pathogenesis and progression of AD363. Research
with DIAD participants has shown that Aβ can become abnormal decades before the onset of
cognitive impairment, and that there are sequential downstream changes in tau phosphorylation,
brain metabolism, structural declines in grey and white matter, and the formation of NFTs362,364–
368

.
The Dominantly Inherited Alzheimer’s Network (DIAN) launched an observational study

of DIAD in 2008361,362,369 and the DIAN-Trials Unit (TU) was established in 2012 as a publicprivate collaboration370–372. The first trial (DIAN-TU-001) was launched in 2012 in
asymptomatic and mildly symptomatic individuals to test two monoclonal antibodies in parallel:
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gantenerumab (an anti-fibrillar Aβ antibody) and solanezumab (an anti-soluble Aβ antibody)372.
The trial was initially a two-year biomarker endpoint and that transitioned to a four-year
treatment trial with a cognitive endpoint372. Although the trial did not reach its cognitive
endpoints within its four-year scope, the administration of gantenerumab lowered levels of Aβ in
the brain as measured using positron emission tomography (PET)373. Using the a priori defined
summary measures no significant effects were observed on volumetric estimates from magnetic
resonance imaging (MRI) or brain metabolism assessed using fluorodeoxyglucose (FDG) PET,
although beneficial effects on neurofilament light chain (NfL) were observed373.
Gantenerumab is a fully human monoclonal antibody that binds and removes aggregated
Aβ by Fc receptor-mediated phagocytosis352,353. Early trials in sporadic AD found significant
dose-dependent reductions in amyloid-β plaque levels in participants receiving Gantenerumab
assessed using florbetapir PET374,375. A substudy of participants enrolled in these trials who
subsequently entered the open-label extensions with titration schedules up to 1200mg every four
weeks showed mean levels of Aβ reduction of 39 Centiloids at year one and 59 Centiloids by
year two, resulting in 37% and 51% of participants having Aβ plaque levels below the Aβ
positivity threshold375. Further results published in these participants demonstrated continued
reduction in Aβ plaque levels with prolonged treatment at 1200mg376. In depth analysis of these
trials also reveal that rather than having a ubiquitous effect across areas of abnormal Aβ
deposition, the degree of Aβ plaque clearance varies regionally375,376. The initial analyses of the
DIAN-TU-001 data373 looked only at prespecified summary neuroimaging variables and did not
account for regional heterogeneity. Examinations of potential regionally specific results, as
performed in these analyses, are critical to fully understand what impact active treatment had on
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levels of Aβ plaques as well as downstream measures of brain metabolism and structural
atrophy.

5.1.2 Materials and Methods
Participants

All data in this analysis was collected during the DIAN-TU-001 trial (trial registration number:
NCT01760005). 211 participants were referred to this trial from DIAN-OBS, DIAN Expanded
Registry, DIAN-TU and partner sites. Eligibility criteria included participants known to have or
at-risk for a DIAD mutation, between 15 years before to 10 years after the expected age of
symptom onset (EYO), and an evaluated Clinical Dementia Rating (CDR) of 0 (cognitively
normal) or 0.5 to 1 (early dementia)377. Participants could choose to remain blinded to their
mutation status; mutation non-carriers were assigned to placebo groups. DIAD mutation carriers
were randomized 3:1 to active or placebo with a minimization procedure378. All study
participants, personnel, and sponsor were blinded to active or placebo assignment. Data from
participants in the DIAN-OBS study who met the DIAN-TU inclusion criteria were used as
natural history controls for improved estimates of the placebo group. The DIAN-OBS and
DIAN-TU have similar protocols, including cognitive, clinical, imaging and biomarker
measures. Statistical evaluation of characteristics for all participants are provided in Table 5.1.
Study Design
DIAN-TU-001 was conducted at 25 sites in 7 countries, from December 2012 through November
2019. Investigators are listed in the supplementary information. Cognitive outcomes were
assessed every 6 months, clinical outcomes annually, and biomarkers at baseline and at years 1,
2, and 4. A common close design ensured double-blind treatment continued for all participants
until the last participant reached 4 years. Based on results of concurrent phase 2 and 3 trials in
125

sporadic Alzheimer’s disease374–376, target drug doses were increased approximately midway or
later through the study. Gantenerumab was increased from 225 mg (subcutaneously, every 4
weeks) to 1200 mg in 2016. Solanezumab was increased from 400 mg (intravenously, every 4
weeks) to 1600 mg in 2017373.
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Table 5.1 Participant characteristics.
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Imaging Methods
Magnetic resonance imaging (MRI) was performed using the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) protocol. T1-weighted images (1.1 x 1.1 x 1.2 mm voxels) were
acquired for all participants on a 3T MRI scanner. The ADNI Imaging Core screened images for
protocol compliance, imaging artifacts, and amyloid related imaging abnormalities (ARIA)379.
Volumetric segmentation and cortical surface reconstruction were completed using FreeSurfer
v5.3 to define cortical and subcortical regions of interest380,381. Segmentations and surface
reconstructions were visually inspected by members of the DIAN-TU Imaging Core and edited
when needed. Subcortical volumes were corrected for intracranial volume using a regression
approach382. Cortical thicknesses and subcortical volumes were summed across hemispheres.
ROIs defined by FreeSurfer on the MRI scans were used for the regional processing of all
PET data. Aβ PET imaging was performed using ¹¹C-Pittsburgh Compound B (¹¹C-PiB) and
18F-fluorodeoxyglucose (FDG) PET imaging was utilized as a marker of brain metabolism.
Scans were processed using an in-house pipeline (https://github.com/ysu001/PUP) that utilizes
the regions of interest defined by FreeSurfer. PiB PET data from the 40-70 min post injection
window and FDG data from the 40-60 min post injection window were converted to standardized
uptake value ratios (SUVRs) using cerebellar grey matter as the reference region383. Data were
partial volume corrected using a geometric transfer matrix approach383,384. A composite to
represent a global measure of Aβ was calculated using the averaged SUVR values in the lateral
orbitofrontal, medial orbitofrontal, precuneus, rostral middle frontal, superior frontal, superior
temporal and middle temporal regions.
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Blood Flow Dataset
Blood flow data was derived using 15O-water from a separate, well-characterized cohort as
previously described385 using age and gender matched control subjects relative to trial
participants. Data were also processed using FreeSurfer ROIs and averaged to generate one
summary blood-flow map.
Safety Measures
Safety assessments included AEs, routine laboratory assessments, physical examinations
including electrocardiogram and MRIs for ARIA.
Statistical Analysis
Methods used to predetermine sample sizes and assign participants to arms were detailed in
previous trial publications371–373.
Linear mixed effects models were constructed in R v4.1.0 using lme4386. Model
equations were structured as follows in pseudocode:
𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 ~ 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 𝑎𝑎𝑎𝑎𝑎𝑎 + 𝑠𝑠𝑠𝑠𝑠𝑠 + 𝐴𝐴𝑝𝑝𝑝𝑝𝑝𝑝4 + 𝐶𝐶𝐶𝐶𝐶𝐶 + 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑎𝑎𝑎𝑎𝑎𝑎 + 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 𝐸𝐸𝐸𝐸𝐸𝐸
+ 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑖𝑖𝑖𝑖 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 + (𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑎𝑎𝑎𝑎𝑎𝑎 × 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 𝐸𝐸𝐸𝐸𝐸𝐸)

+ (𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑎𝑎𝑎𝑎𝑎𝑎 × 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑖𝑖𝑖𝑖 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠) + (𝐸𝐸𝐸𝐸𝐸𝐸 × 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑖𝑖𝑖𝑖 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠)

+ (𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑎𝑎𝑎𝑎𝑎𝑎 × 𝐸𝐸𝐸𝐸𝐸𝐸 × 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑖𝑖𝑖𝑖 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠) + (𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑖𝑖𝑖𝑖 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 || 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠)

Random subject intercepts and slopes were included to accommodate individual
variation. Models were performed with an unstructured covariance matrix to account for
potential dependencies in longitudinal measurements. Models were constructed for the global
summary measure of Aβ as well as for regional estimates of PiB, FDG, and structural MRI. FDR
correction was used for multiple comparisons correction on regional analyses with statistical
significance for all analyses set at a corrected p < 0.05. Regional analyses and brainmaps utilized
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the beta weight of the drug arm × time in study two-way interaction term from LME models to
quantify the estimated longitudinal effect of Gantenerumab use on imaging variables. The threeway interaction term drug arm × EYO × time in study was included to account for potential
changes in observed longitudinal drug effect as a function of disease state. Correlations of
regional imaging variables with regional estimated drug effect beta weights were performed
using Pearson correlations.

5.1.3 Results

DIAD mutation carriers were randomized 3:1 to active or placebo drug arms with a robust
minimization procedure378 as previously described372,373. This procedure was used in order to
minimize between-group differences at baseline in all relevant participant statistics including
genetic, cognitive, imaging, and disease state categories (Table 5.1). At baseline, 57% of
participants were considered cognitively normal (CDR 0) and 43% of participants were
considered cognitively impaired (CDR >0). Baseline mean amyloid burden across the groups
was 64 Centiloids with a wide standard deviation reflecting a large within-group diversity of
disease states while maintaining between-group integrity (Table 5.1).
Treatment with Gantenerumab significantly reduced the longitudinal increase of mean
cortical PiB PET signal (β = -.16, SE = .026, df =78.38, t = -5.94, p = 2.54e-07 [benefit is neg.])
relative to the placebo group (Figure 5.1). Additionally, Gantenerumab treatment significantly
reduced longitudinal PiB PET in 32 cortical and 6 subcortical regions (Table 5.2, Figure 5.2,
Supp. Table 1). The strength of the drug effect on longitudinal PiB PET values varied
considerably with the most significant drug effects seen in the dorsal striatum (caudate β = -.38,
SE = .043, df = 83.91, t = -8.82, p = 3.07e-12 ; putamen β = -.31, SE = .033, df = 85.16, t = 9.21, p = 8.72e-13 ), thalamus (β = -.17, SE = .023, df = 91.68, t = -7.79, p = 1.44e-10 ), nucleus
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accumbens (β = -.31, SE = .048, df = 81.23, t = -6.51, p = 3.28e-08 ), anterior cingulate (caud.
ant. cingulate β = -.23, SE = .034, df = 80.68, t = -6.899, p = 9.43e-09 ; rost. ant. cingulate β = .23, SE = .034, df = 80.59, t = -6.842, p = 1.02e-08 ) and medial orbitofrontal (β = -.21, SE =
.034, df = 86.67, t = -6.43, p = 3.34e-08) regions.
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Figure 5.1. Relationship of longitudinal Gantenerumab use on key PiB PET signal levels. Group-level mean PiB
PET SUVR values at each imaging time point during the trial for A) mean cortical composite, B) mean cortical
composite split by CDR, D) Caudate, and E) Caudate split by CDR. Linear mixed effects models were used to
quantify longitudinal drug effects. C) Mean cortical PiB PET or F) Caudate PiB PET was dependent variable, with
fixed effects covariates age, sex, CDR, ApoE4 status, and drug x time interaction term, and subject specific random
slopes and intercepts were modeled.
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Table 5.2. Regional LME model outputs for the drug arm * time in study model component. Component estimates
(β weights) represent the total effect of the predictor variable on longitudinal regional PiB PET signal over the trial
period.
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Figure 5.2. Regional differences in estimated drug effect on PiB PET signal levels. Top) Regional linear mixed
effects models were used to estimate the effect of longitudinal Gantenerumab use on PiB PET signal. Regional PiB
PET signal was dependent variable, with fixed effects covariates age, sex, CDR, ApoE4 status, and drug x time
interaction term, and subject specific random slopes and intercepts were modeled. Beta weights for the drug x time
interaction term are displayed. Bottom) Regional mean baseline PiB PET signal for trial participants.
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Many of the regions with high drug effects also have prominent cross-sectional levels of
PiB PET, although posterior cortical structures with prominent baseline PiB PET signal showed
noticeably smaller, but still significant drug effects (precuneus β = -.16, SE = .032, df = 77.91, t
= -5.14, p = 3.65e-06 ; posterior cingulate β = -.17, SE = .032, df = 70.48, t = -5.22, p = 3.39e-06
; isthmus cingulate β = -.11, SE = .024, df = 72.73, t = -4.61, p = 2.43e-05 ). When directly
comparing the spatial pattern of regional estimated drug effects to regional baseline estimates of
pathology there was a strong spatial correlation of r(140) = .75, p = 2e-08. When comparing the
spatial pattern of regional estimated drug effects to regional blood flow data from a separate age
and sex matched cohort the spatial correlation was r(140) = .36, p = .02. No statistically
significant drug effects were found in the regional analyses for FDG or MRI.

5.1.4 Discussion

Top-line results from the DIAN-TU-001 trial demonstrated a significant effect of active drug on
global Aβ load clearance. The current analyses additionally revealed in detail that the estimated
effectiveness of Gantenerumab was not ubiquitous across the brain but varied by region with the
greatest effects observed in the basal ganglia and medial frontal regions. Recognizing, and
understanding, what drives these spatial patterns is of high interest as it may elucidate the way
the drug is behaving in the brain to inform future clinical trials.
A major contributing factor to these regional differences is the baseline level of
Aβ pathology in each region prior to drug administration as evident by the spatial similarity
between the two (Figure 4.2) and that cognitively impaired participants (CDR >0), whom have
greater levels of baseline Aβ pathology, demonstrated more Aβ clearance over the course of the
trial than asymptomatic participants. However, data presented here suggests that this relationship
cannot solely explain the regional differences in estimated drug effects. In both sporadic and
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DIAD posterior parietal regions are one of the earliest regions to demonstrate Aβ deposition and
reach the highest levels of pathology accumulation387,388. In DIAD there is also substantial
buildup of Aβ in the basal ganglia, although to a lesser extent than both parietal and medial
frontal regions387–389. The current results show the greatest estimated drug effect was seen in the
basal ganglia and medial frontal regions of the brain with more modest, albeit significant, effects
in posterior parietal regions. This suggests that drug effects are not solely proportional to
baseline levels of pathology and are being influenced by other factors.
It is possible that it is a unique feature of the DIAD cohort that is driving the observed
spatial pattern. Prior work has shown that Aβ accrual in the striatum is a feature of DIAD as well
as Down Syndrome389 but not sporadic AD. This could potentially explain these regions having
some of the greatest reductions in the current analyses. However, evidence from previous trials
in sporadic AD using Gantenerumab also show similar regional variability, with the greatest
amount of Aβ load clearance also being in the basal ganglia and medial frontal cortex375,376. The
consistent spatial patterns suggest a common mechanism.
If the pattern is not driven by the cohort, it is likely tied to the specific regions.
Previous research has demonstrated that blood flow levels vary regionally across the brain390,
and this could cause different levels of drug delivery, and therefore pathology clearance.
However, we show here that mean regional blood flow levels in an age and gender matched
cohort is not significantly correlated with regional estimated drug effects (Figure 4.2). It may not
be overall blood flow that determines drug access though, but rather blood-brain-barrier
permeability390. Anecdotal evidence from clinical trials has shown incidences where ARIA was
associated with a corresponding local clearance of plaques interpreted as being due to increased
drug accessibility. Finally, there is evidence that lymphatic systems play a role in regulating CSF
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flow in the brain391. It may be that regional exposure to the drug is modulated by both blood flow
as well as subsequent clearance from the brain.
Histopathological examinations have classified an array of different plaque types
occurring in the brain, potentially representing different stages in the life cycle of plaque
development392–394 and that this evolution varies regionally in the brain395. Given that
pharmacodynamic studies of Gantenerumab show specific binding to fibrillar Aβ at sites on the
N-terminal and spatially adjacent central Aβ sequences352,354, it is possible that Gantenerumab
displays a different affinity for, and therefore a different clearance rate, for each specific type of
Aβ plaque depending upon the availability of these binding sites. It is possible such a
phenomenon is why medial frontal regions and basal ganglia structures displayed higher drug
effects and parietal structures displayed lower estimated drug effect levels, respectively, than
their baseline levels of Aβ load would suggest.
Limitations
Although we found significant reduction in PiB PET signal during the four-year trial period, we
found no evidence of significant alterations of the downstream imaging markers of FDG PET or
MRI. Prior analyses of cerebrospinal fluid did reveal a positive effect on NfL levels373, indicating
at least some modification of neurodegeneration processes. This lack of imaging results could be
due to multiple causes. Being aggregate measures, which include prior damage, neuroimaging
may take a longer time period to demonstrate downstream effects. The four-year trial length,
coupled with the dose escalation protocol mid-trial, meant that participants only received the
highest doses of Gantenerumab between years 2 and 4. Marked increases in Aβ clearance were
observed during this time, suggesting that even more significant effects of Gantenerumab could
have been observed if higher doses were administered throughout the trial. Despite significant
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reductions, many participants still had abnormal levels of Aβ. It may be only when Aβ are
sufficiently reduced to normal levels that neurodegenerative markers substantially improve.
Finally, tau PET imaging was introduced late in the trial preventing us from relating Aβ
reductions to this key marker of neurofibrillary pathology. The extension of the DIAN TU-001
into a two-year open-label extension should address these questions.

5.1.5 Conclusions

In this study, we showed that treatment with Gantenerumab significantly reduced global PiB
PET signal in DIAD participants over a four-year trial period. This estimated drug effect was not
ubiquitous across the brain but varied regionally, with the highest levels of signal reduction in
the basal ganglia and medial frontal structures. Regional variations in PiB results were correlated
but not solely explained by levels of baseline Aβ pathology present in each region. We did not
find any evidence of improvement in downstream imaging biomarkers over the four-year trial
period. These findings suggest that prolonged use of Gantenerumab is effective in significantly
reducing PiB PET signal, although future work is needed to link reductions in Aβ to clinical and
neurodegenerative change.
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Chapter 6: Conclusions
6.1 Overall Summary

In the introduction of this dissertation, we detailed recent advancements in disease modifying
therapies designed to target and neutralize specific aspects of AD pathology progression. Despite
the bleeding-edge nature of these advancements, they represent the most promising avenue that
we have for treating the millions of people affected by AD around the world. We also detailed
the immense difficulties that large-scale therapy delivery would entail, given the significant
monetary outlay and difficulty of administration that would be required. The field of AD
research is navigating a transition period from simply trying to understand the intricacies of
pathology evolution at a population level to needing to provide insights about treatment
administration at an individual level.
In order to fulfill this need, we must improve our understanding of sources of individual
pathology variation and how they impact each aspect of pathology progression (Figure 1.3A).
We must also find ways to better integrate this improved understanding into detailed disease
progression models that are able to account for large numbers of trajectory modifiers (Figure
1.3B). Finally, we must develop a detailed understanding of how state of the art therapies work
in practice, and how this translates to pathology trajectory deflection and symptom modification
(Figure 1.3C).
This dissertation provided valuable contributions addressing these three key areas.
Chapters 2 and 3 describe work that extends our understanding of key sources of pathology
variation both from within the pathological cascade (Figure 1.3 A1) and from external health
factors (Figure 1.3 A2 & A3). Chapter 4 explores the application of a modeling strategy that can
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account for large amounts of pathology modifiers and provide individual-level predictions of
progression (Figure 1.3 B1). Chapter 5 extends our knowledge of a state-of-the-art disease
modifying therapy and how its use affects pathology levels of both its primary target and other
aspects of the pathological cascade (Figure 1.3 C1).

6.2 Comments on Chapter 2

Chapter 2 presented analysis aimed at elucidating the relationship between cortical thinning, as
measured by structural MRI, and NFT pathology buildup measured with tau PET. A large
amount of prior work demonstrated that cortical thinning measured by structural MRI is a
sensitive marker to both AD dementia and preclinical AD, and further work has established
significant relationships between cortical thinning and both amyloid-β and tau pathology
independently. We found that levels of tau PET binding, rather than amyloid-β PET, were
significantly related to cortical thinning and antecedent structural atrophy. When considering
both biomarkers in LME models, levels of tau PET signal remained significantly related to
cortical thickness while the relationship of amyloid-β with cortical thickness was drastically
reduced. This result suggests that prior work showing a significant relationship between cortical
thinning and amyloid-β pathology may have been due to the concurrent presence of both
amyloid-β, tau NFT pathology, and cortical thinning in many regions of the AD brain. However,
the advent of tau PET imaging allows observation of the much stronger relationship between tau
NFT pathology and cortical thinning. The severity of reduction in the observed Aβ-cortical
thinning relationship when tau PET is included in models suggests that the tau-cortical thinning
relationship is independent from the influence of amyloid β, rather than some combination of the
influence of both pathologies.
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Regional models show that the association between tau PET signal and cortical thinning
was not restricted to just the medial temporal lobe, but maintained significance in several regions
within the temporal, parietal, and frontal lobes. Spatial maps of the tau-cortical thinning
relationship show particular similarity to both spatial patterns of atrophy in AD and spatial
patterns of tau NFT accumulation seen in prior work.
AD pathological models show changes in tau occur before structural changes seen with
MRI, which would suggest that tau pathology would be a stronger predictor of future pathology
rather than retrospective cortical thinning. Due to the constraint of having only cross-sectional
tau data at the time of analysis, we instead showed that NFT pathology measured with tau PET is
related to cross-sectional cortical thinning and atrophy that occurred in preceding years. We also
found that rates of MRI change were related to current levels of amyloid-β, although there is
strong evidence that amyloid-β deposition precedes all other pathologies to a considerable
degree. This suggests that pathology deposition leading cortical thinning with a time lag could
still account for these results, even if looking at antecedent atrophy is not the correct causative
temporal direction. Rates of structural atrophy may just be serving as a rough marker of disease
stage in each region.
Alternatively, proposed pathology models up until the time of writing were based on
measures of CSF t-tau and p-tau, which are only modestly correlated to tau PET signal and likely
measure slightly different aspects of tau pathology. A temporal delay between CSF and PET
measures of amyloid-β is well known in prior work, so a lag between CSF tau and tau PET is
also likely. This lag could push tau PET measures later in the disease progression and more
proximal to structural MRI changes.
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This study was one of the first to model concurrent amyloid-β and tau PET signal as
predictors of structural MRI changes, and to show the significantly stronger association of tau
PET and cortical thinning. This result lends further support to prior work positing that tau NFT
pathology is the main driver of structural atrophy in AD. The spatial presentation of tau
pathology in AD has been shown to be more heterogeneous between individuals than diffuse
cortical amyloid-β pathology, suggesting that tau pathology could be a source of pathology
variance with respect to structural atrophy and resulting cognitive symptoms. Further work
should look to understand how tau pathology heterogeneity is generated, and examine the
longitudinal effects of tau pathology on differences in structural atrophy and symptom
generation.

6.3 Comments on Chapter 3

Section 3.1 presented evidence that key measures of sleep quality and AD pathology have an
inverse relationship in DIAD participants. We showed that NREM SWA decreases with
increasing amyloid-β deposition and tau accumulation. This relationship was strongest with tau
PET and CSF tau/Aβ42 ratio. For tau PET, several regions known to be involved with AD
progression showed associations with decreased NREM SWA including entorhinal,
parahippocampal, orbitofrontal, and inferior parietal regions. Furthermore, the spatial pattern of
tau PET-NREM SWA relationship is similar to structural imaging changes observed in AD.
As discussed in this paper, prior work in both mice and humans has provided evidence
for a bidirectional relationship between sleep and AD pathology. Increased AD pathology causes
disruptions in sleep quality and circadian rhythm function, likely through disruptions in the
neural circuitry and signaling needed to initiate and maintain these processes. In turn, poor sleep
causes increases in buildup of AD pathologies, likely by disrupting the normal clearance of
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cellular debris and metabolites through interstitial fluid bulk flow present with quality sleep.
Taken together, these effects could form a feedforward loop in which increasingly worse sleep
and increasingly higher AD pathology buildup cause acceleration in disease progression.
Many factors outside of AD pathology can have profound impacts on sleep quality. There
are extensive bodies of literature detailing sleep disordered breathing conditions, the effects of
obesity and diabetes on sleep quality, decreasing sleep quality with normal aging, and the effect
of high stress levels on sleep quality. All these factors are common in cohorts at risk of AD and
could contribute on an individual basis to the progression of pathology, either directly or through
disruption of sleep quality. Future work should seek to understand the relationship between AD
pathology and sleep quality over a longer time period in order to better estimate the long-term
effects of this relationship on patient outcomes.
Section 3.2 examined the relationship between BMI and amyloid-β as measured by PiB
PET in mid- and late-life participants. Prior work suggested that there might be a relationship
between obesity and the risk of developing dementia, but also hinted at the complexity of the
relationship via contradictory conclusions from numerous studies. We found that higher BMI
was associated with lower cortical Aβ burden in cognitively normal late-life participants.
Although this result is contradictory to studies that have shown that high BMI is associated with
adverse health outcomes, higher BMI specifically in late-life has been shown to be predictive of
good health status, reduced risk of dementia, and better cognitive performance. In this respect,
results from this analysis supports at least one component of the oft mentioned ‘obesity paradox’.
Results from mid-life participants in this study may not have reflected prior works’
assertion that high BMI is associated with greater risk of developing AD due to cognitively
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normal mid-life participants having relatively little amyloid-β pathology to observe. The
complex nature of analyzing PET data at low signal levels could obscure results that may come
to light given greater longitudinal data.

6.4 Comments on Chapter 4

Chapter 4 explores the application of a machine learning (ML) based modeling strategy to model
pathology progression in a DIAD cohort. Unlike traditional statistical modeling strategies, ML
strategies can provide pathology progression and clinical outcome predictions at the individuallevel and excel at discovering patterns in high-dimensional data that underlie complex
pathological progression and clinical phenotypes. These individual-level predictions could
enable the personalization of care and treatments and open avenues for targeted care. Prior to this
work, much of the ML work within AD focused on classification of individuals into MCI and/or
AD groups in LOAD. While this might provide valuable help with initial clinical diagnosis, its
value is limited to only a few points in the disease trajectory. We chose to use DIAD subjects, as
time until conversion to symptomatic impairment (EYO) can be estimated throughout the disease
course providing an anchor point to make predictions about pathology evolution at future time
points in the disease.
Our models demonstrated high accuracy in predicting future amyloid accumulation,
changes in metabolism, and brain atrophy in ADAD several years into the future. Using feature
selection methods, we identified several brain regions that are both common among multiple
modalities as well as regions that are unique to each modality. Because our models were trained
on the largest available DIAD dataset with a variety of demographic variables, we can easily
generate individualized predictions specific to a give set of demographics. This model of
including variables could be extended to any number of potential disease modifying factors (i.e.
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sleep quality, diet and exercise habits, administration of a disease modifying therapy) to provide
actionable individual-level insights to clinicians and researchers. Additionally, accurate
identification of individuals whose progression patterns differ substantially from model
predictions could inform researchers about sources of pathology variation that have yet to be
adequately accounted for.

6.5 Comments on Chapter 5

Chapter 5 details analyses from neuroimaging data gathered during the DIAN-TU-001 trial
demonstrating significant reductions in PiB PET signal with prolonged use of the anti-amyloid
monoclonal antibody gantenerumab. Further analysis revealed that the estimated effectiveness of
gantenerumab use was not ubiquitous across the brain but varied by region with the greatest
effects observed in the basal ganglia and medial frontal regions. Estimated regional levels of
drug effectiveness were strongly correlated with levels of baseline amyloid-β pathology, but did
not solely explain the regional variability in effectiveness estimates. Despite some differences in
spatial presentation of amyloid-β deposition between LOAD and DIAD, results presented in this
chapter and prior work in LOAD demonstrates the greatest estimates of drug effectiveness in
basal ganglia and medial frontal regions. Agreement between LOAD and DIAD cohorts suggest
results are not driven by a unique feature of one cohort versus another.
If regional differences in drug effectiveness are not being driven by a unique feature of
the cohort, they are likely tied to differences in the specific brain regions. Previous research has
demonstrated that blood flow levels vary by region across the brain, which could cause differing
levels of drug delivery and pathology clearance. Alternatively, prior histopathology work has
classified an array of amyloid plaque types that occur in the brain and shown that these types

145

vary regionally. It is possible, given its specific binding parameters, that gantenerumab displays a
different clearance rate for different types of plaques.
We found no evidence of significant alterations in downstream imaging biomarkers over
the course of the four-year trial period. Consistent with concurrent trials of gantenerumab in
sporadic AD populations, top line trial results from DIAN-TU-001 also failed to report cognitive
improvements in participants during the trial. Lack of these downstream effects represents a
significant gap in our understanding of how AD pathologies interact to generate cortical atrophy
and cognitive deficits in participants. Given the timeline of pathological modifications suggested
in widely accepted models, it is possible that a four-year study did not provide a long enough
time window to see any knock-on effects of reducing amyloid pathology in participants.
Alternatively, the initiation of amyloid-β pathology buildup might serve as the initiation point of
eventual downstream pathological changes which then proceed relatively independent of
amyloid-β deposition. In either case, initiating treatment as early as possible within the disease
course would be vital to treatment effectiveness. Further studies should seek to characterize the
effects of gantenerumab use at increased time windows and with earlier administration points
within the disease course in order to better understand these relationships.

6.6 Overall Conclusions

Taken together, these studies have characterized several key sources of individual pathology
variation, both from within the pathological cascade and from external health factors. These
sources were shown to be influential in affecting key aspects of AD pathology progression and
could work synergistically to produce dramatic effects on overall disease progression and
symptomatology (Figure 1.3A). We also showed that the effectiveness of a state-of-the-art
disease modifying therapy can be modified by aspects of existing pathology and highlighted the
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need for deeper understanding of how potential therapies deflect target pathology levels and the
effects this causes on downstream pathology progression (Figure 1.3C). We additionally
proposed a potential mechanism for integrating these sources of variation into a pathology
progression model that could provide actionable individual-level insights to clinicians and
researchers (Figure 1.3B).
As the field of AD research approaches the inflection point of moving from disease
characterization at a group level to treatment selection, administration, and monitoring at the
patient level, it is vital to remember that all these sources of pathology variation converge to
form the overall disease state of each patient. As the general lack of cognitive improvement
shown in therapy trials until this point shows, treating a single aspect of the influences on
pathology progression without considering the broader landscape of patient health reduces the
chance for ultimately successful outcomes. We must make the changes necessary to maximize
the chance for successful treatment of AD pathology within the constraints posed by this
complex and long-developing disease.
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